Glucagon-like peptide analogues for type 2 diabetes mellitus
Deepson S Shyangdan, Pamela Royle, Christine Clar, Pawana Sharma, Norman Waugh, Alisa Snaith, Deepson S Shyangdan, Pamela Royle, Christine Clar, Pawana Sharma, Norman Waugh, Alisa Snaith
Abstract
Background: Glucagon-like peptide analogues are a new class of drugs used in the treatment of type 2 diabetes that mimic the endogenous hormone glucagon-like peptide 1 (GLP-1). GLP-1 is an incretin, a gastrointestinal hormone that is released into the circulation in response to ingested nutrients. GLP-1 regulates glucose levels by stimulating glucose-dependent insulin secretion and biosynthesis, and by suppressing glucagon secretion, delayed gastric emptying and promoting satiety.
Objectives: To assess the effects of glucagon-like peptide analogues in patients with type 2 diabetes mellitus.
Search strategy: Studies were obtained from electronic searches of The Cochrane Library (last search issue 1, 2011), MEDLINE (last search March 2011), EMBASE (last search March 2011), Web of Science (last search March 2011) and databases of ongoing trials.
Selection criteria: Studies were included if they were randomised controlled trials of a minimum duration of eight weeks comparing a GLP-1 analogue with placebo, insulin, an oral anti-diabetic agent, or another GLP-1 analogue in people with type 2 diabetes.
Data collection and analysis: Data extraction and quality assessment of studies were done by one reviewer and checked by a second. Data were analysed by type of GLP-1 agonist and comparison treatment. Where appropriate, data were summarised in a meta-analysis (mean differences and risk ratios summarised using a random-effects model).
Main results: Seventeen randomised controlled trials including relevant analyses for 6899 participants were included in the analysis. Studies were mostly of short duration, usually 26 weeks.In comparison with placebo, all GLP-1 agonists reduced glycosylated haemoglobin A1c (HbA1c) levels by about 1%. Exenatide 2 mg once weekly and liraglutide 1.8 mg reduced it by 0.20% and 0.24% respectively more than insulin glargine. Exenatide 2 mg once weekly reduced HbA1c more than exenatide 10 μg twice daily, sitagliptin and pioglitazone. Liraglutide 1.8 mg reduced HbA1c by 0.33% more than exenatide 10 μg twice daily. Liraglutide led to similar improvements in HbA1c compared to sulphonylureas but reduced it more than sitagliptin and rosiglitazone.Both exenatide and liraglutide led to greater weight loss than most active comparators, including in participants not experiencing nausea. Hypoglycaemia occurred more frequently in participants taking concomitant sulphonylurea. GLP-1 agonists caused gastrointestinal adverse effects, mainly nausea. These adverse events were strongest at the beginning and then subsided. Beta-cell function was improved with GLP-1 agonists but the effect did not persist after cessation of treatment.None of the studies was long enough to assess long-term positive or negative effects.
Authors' conclusions: GLP-1 agonists are effective in improving glycaemic control.
Conflict of interest statement
None known.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-AFig-FIG01.jpg)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-AFig-FIG02.jpg)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-AFig-FIG03.jpg)
![Analysis 1.2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-001-02.jpg)
![Analysis 1.5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-001-05.jpg)
![Analysis 2.1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-002-01.jpg)
![Analysis 2.2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-002-02.jpg)
Analysis 2.3
Comparison 2 Exenatide 2 mg…
Analysis 2.3
Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 3 Hypoglycaemia (minor).
Analysis 2.4
Comparison 2 Exenatide 2 mg…
Analysis 2.4
Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 4 Weight change…
Analysis 2.8
Comparison 2 Exenatide 2 mg…
Analysis 2.8
Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 8 Fasting plasma…
Analysis 3.1
Comparison 3 Exenatide 2 mg…
Analysis 3.1
Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 1 HbA1c…
Analysis 3.2
Comparison 3 Exenatide 2 mg…
Analysis 3.2
Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 2 HbA1c…
Analysis 3.3
Comparison 3 Exenatide 2 mg…
Analysis 3.3
Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia…
Analysis 3.4
Comparison 3 Exenatide 2 mg…
Analysis 3.4
Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 4 Weight…
Analysis 3.8
Comparison 3 Exenatide 2 mg…
Analysis 3.8
Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 8 Fasting…
Analysis 4.1
Comparison 4 Exenatide 2 mg…
Analysis 4.1
Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 1 HbA1c…
Analysis 4.2
Comparison 4 Exenatide 2 mg…
Analysis 4.2
Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 2 HbA1c…
Analysis 4.3
Comparison 4 Exenatide 2 mg…
Analysis 4.3
Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 3 Hypoglycaemia…
Analysis 4.4
Comparison 4 Exenatide 2 mg…
Analysis 4.4
Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 4 Hypoglycaemia…
Analysis 4.6
Comparison 4 Exenatide 2 mg…
Analysis 4.6
Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 6 Weight…
Analysis 4.9
Comparison 4 Exenatide 2 mg…
Analysis 4.9
Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 9 Fasting…
Analysis 5.1
Comparison 5 Liraglutide 0.6 mg…
Analysis 5.1
Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 1 HbA1c (%).
Analysis 5.2
Comparison 5 Liraglutide 0.6 mg…
Analysis 5.2
Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 2 HbA1c
Analysis 6.1
Comparison 6 Liraglutide 0.9 mg…
Analysis 6.1
Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 1 HbA1c (%).
Analysis 6.2
Comparison 6 Liraglutide 0.9 mg…
Analysis 6.2
Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 2 HbA1c
Analysis 7.1
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.1
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 1 HbA1c.
Analysis 7.2
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.2
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 2 HbA1c
Analysis 7.3
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.3
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 3 Hypoglycaemia.
Analysis 7.4
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.4
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 4 Weight change.
Analysis 7.6
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.6
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 6 Systolic blood pressure.
Analysis 7.7
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.7
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 7 Fasting plasma glucose (mmol/L).
Analysis 7.9
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.9
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 9 Triglycerides (mmol/L).
Analysis 7.10
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.10
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 10 Total cholesterol (mmol/L).
Analysis 7.11
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.11
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 11 HDL‐cholesterol (mmol/L).
Analysis 7.12
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.12
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 12 LDL‐cholesterol (mmol/L).
Analysis 8.1
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.1
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 1 HbA1c.
Analysis 8.2
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.2
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 2 HbA1c
Analysis 8.3
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.3
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 3 Hypoglycaemia.
Analysis 8.4
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.4
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 4 Weight change.
Analysis 8.6
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.6
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 6 Systolic blood pressure.
Analysis 8.7
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.7
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 7 Fasting plasma glucose (mmol/L).
Analysis 8.9
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.9
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 9 Triglycerides (mmol/L).
Analysis 8.10
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.10
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 10 Total cholesterol (mmol/L).
Analysis 8.11
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.11
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 11 HDL‐cholesterol (mmol/L).
Analysis 8.12
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.12
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 12 LDL‐cholesterol (mmol/L).
Analysis 9.1
Comparison 9 Liraglutide 1.2 mg…
Analysis 9.1
Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 1 HbA1c.
Analysis 9.2
Comparison 9 Liraglutide 1.2 mg…
Analysis 9.2
Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 2 Patients reaching HbA1c…
Analysis 9.3
Comparison 9 Liraglutide 1.2 mg…
Analysis 9.3
Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 3 Weight.
Analysis 9.4
Comparison 9 Liraglutide 1.2 mg…
Analysis 9.4
Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 4 Systolic blood pressure.
Analysis 10.1
Comparison 10 Liraglutide versus insulin…
Analysis 10.1
Comparison 10 Liraglutide versus insulin glargine, Outcome 1 HbA1c.
Analysis 10.2
Comparison 10 Liraglutide versus insulin…
Analysis 10.2
Comparison 10 Liraglutide versus insulin glargine, Outcome 2 HbA1c
Analysis 10.3
Comparison 10 Liraglutide versus insulin…
Analysis 10.3
Comparison 10 Liraglutide versus insulin glargine, Outcome 3 Hypoglycaemia.
Analysis 10.4
Comparison 10 Liraglutide versus insulin…
Analysis 10.4
Comparison 10 Liraglutide versus insulin glargine, Outcome 4 Weight change.
Analysis 10.6
Comparison 10 Liraglutide versus insulin…
Analysis 10.6
Comparison 10 Liraglutide versus insulin glargine, Outcome 6 Systolic blood pressure.
Analysis 10.7
Comparison 10 Liraglutide versus insulin…
Analysis 10.7
Comparison 10 Liraglutide versus insulin glargine, Outcome 7 Fasting plasma glucose (mmol/L).
Analysis 11.1
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.1
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 1 HbA1c (%).
Analysis 11.2
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.2
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 2 HbA1c
Analysis 11.3
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.3
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia (mild/moderate/overall).
Analysis 11.5
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.5
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 5 Weight change.
Analysis 11.9
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.9
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma glucose…
Analysis 12.1
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.1
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 1 HbA1c (%).
Analysis 12.2
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.2
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 2 HbA1c
Analysis 12.3
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.3
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia.
Analysis 12.5
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.5
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 5 Weight change (kg).
Analysis 12.9
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.9
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma glucose…
Analysis 13.1
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.1
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 1 HbA1c (%).
Analysis 13.2
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.2
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 2 HbA1c
Analysis 13.3
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.3
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia (mild/moderate/overall).
Analysis 13.5
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.5
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change…
Analysis 13.7
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.7
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood…
Analysis 13.9
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.9
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma…
Analysis 14.1
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.1
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 1 HbA1c (%).
Analysis 14.2
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.2
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 2 HbA1c
Analysis 14.3
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.3
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia.
Analysis 14.5
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.5
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change…
Analysis 14.7
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.7
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood…
Analysis 14.9
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.9
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma…
Analysis 15.2
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.2
Comparison 15 Lixisenatide versus placebo, Outcome 2 HbA1c
Analysis 15.3
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.3
Comparison 15 Lixisenatide versus placebo, Outcome 3 Symptomatic hypoglycaemia.
Analysis 15.4
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.4
Comparison 15 Lixisenatide versus placebo, Outcome 4 Weight change (kg).
Analysis 15.6
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.6
Comparison 15 Lixisenatide versus placebo, Outcome 6 Fasting plasma glucose (mmol/L).
Analysis 15.7
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.7
Comparison 15 Lixisenatide versus placebo, Outcome 7 Post‐prandial glucose (mmol/L).
Analysis 15.8
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.8
Comparison 15 Lixisenatide versus placebo, Outcome 8 Average self‐monitored 7‐point blood glucose (mmol/L).
Analysis 16.1
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.1
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 1 HbA1c.
Analysis 16.3
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.3
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 3 HbA1c
Analysis 16.4
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.4
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 4 Hypoglycaemia.
Analysis 16.5
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.5
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 5 Weight change.
Analysis 16.8
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.8
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 8 Systolic blood pressure.
Analysis 16.10
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.10
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 17.1
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.1
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 1 HbA1c (%).
Analysis 17.3
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.3
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 3 HbA1c
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 4 Hypoglycaemia.
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 5 Weight change (kg).
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 8 Systolic blood pressure…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 10 Fasting plasma glucose…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo, Outcome 1 HbA1c (%).
Analysis 18.3
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.3
Comparison 18 Taspoglutide versus placebo, Outcome 3 HbA1c
Analysis 18.5
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.5
Comparison 18 Taspoglutide versus placebo, Outcome 5 Hypoglycaemia.
Analysis 18.7
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.7
Comparison 18 Taspoglutide versus placebo, Outcome 7 Weight change (kg).
Analysis 18.11
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.11
Comparison 18 Taspoglutide versus placebo, Outcome 11 Fasting plasma glucose (mmol/L).
Analysis 19.4
Comparison 19 LY2189265 versus placebo,…
Analysis 19.4
Comparison 19 LY2189265 versus placebo, Outcome 4 Weight change (kg).
Analysis 19.6
Comparison 19 LY2189265 versus placebo,…
Analysis 19.6
Comparison 19 LY2189265 versus placebo, Outcome 6 Systolic blood pressure (mm Hg).
Analysis 19.7
Comparison 19 LY2189265 versus placebo,…
Analysis 19.7
Comparison 19 LY2189265 versus placebo, Outcome 7 Diastolic blood pressure (mm Hg).
Analysis 20.1
Comparison 20 GLP‐1 agonist versus…
Analysis 20.1
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 1 HbA1c.
Analysis 20.2
Comparison 20 GLP‐1 agonist versus…
Analysis 20.2
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 2 HbA1c
Analysis 20.3
Comparison 20 GLP‐1 agonist versus…
Analysis 20.3
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 3 Hypoglycaemia.
Analysis 20.5
Comparison 20 GLP‐1 agonist versus…
Analysis 20.5
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 5 Weight change.
Analysis 20.9
Comparison 20 GLP‐1 agonist versus…
Analysis 20.9
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 9 Systolic blood pressure.
Analysis 20.10
Comparison 20 GLP‐1 agonist versus…
Analysis 20.10
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 20.12
Comparison 20 GLP‐1 agonist versus…
Analysis 20.12
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 12 Triglycerides (mmol/L).
Analysis 20.13
Comparison 20 GLP‐1 agonist versus…
Analysis 20.13
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 13 Total cholesterol (mmol/L).
Analysis 20.14
Comparison 20 GLP‐1 agonist versus…
Analysis 20.14
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 14 HDL‐cholesterol (mmol/L).
Analysis 20.15
Comparison 20 GLP‐1 agonist versus…
Analysis 20.15
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 15 LDL‐cholesterol (mmol/L).
- [Efficacy of GLP-1-analogs in type 2 diabetes mellitus].Schütt M. Schütt M. Dtsch Med Wochenschr. 2013 Jan;138(1-2):15. doi: 10.1055/s-0032-1329135. Epub 2012 Dec 18. Dtsch Med Wochenschr. 2013. PMID: 23250688 German. No abstract available.
- Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Hemmingsen B, et al. Cochrane Database Syst Rev. 2017 May 10;5(5):CD012204. doi: 10.1002/14651858.CD012204.pub2. Cochrane Database Syst Rev. 2017. PMID: 28489279 Free PMC article. Review.
- Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis.Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR. Shyangdan DS, et al. BMC Endocr Disord. 2010 Dec 9;10:20. doi: 10.1186/1472-6823-10-20. BMC Endocr Disord. 2010. PMID: 21143938 Free PMC article.
- Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S. Waugh N, et al. Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Health Technol Assess. 2010. PMID: 20646668 Review.
- Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Htike ZZ, et al. Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17. Diabetes Obes Metab. 2017. PMID: 27981757 Review.
- Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.Pinelli NR, Hurren KM. Pinelli NR, et al. Ann Pharmacother. 2011 Jul;45(7-8):850-60. doi: 10.1345/aph.1Q024. Epub 2011 Jul 5. Ann Pharmacother. 2011. PMID: 21730278 Review.
- Effects of synbiotics supplementation on anthropometric and lipid profile parameters: Finding from an umbrella meta-analysis.Musazadeh V, Mohammadi Anilou M, Vajdi M, Karimi A, Sedgh Ahrabi S, Dehghan P. Musazadeh V, et al. Front Nutr. 2023 Feb 23;10:1121541. doi: 10.3389/fnut.2023.1121541. eCollection 2023. Front Nutr. 2023. PMID: 36908920 Free PMC article.
- Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients.Silva-Nunes J, Nascimento E, Louro J, Dores J, Laginha T, Gonçalves-Ferreira A, Alves M, Souto SB, Cunha N, Pina E, Duarte R, Raposo JF. Silva-Nunes J, et al. Metabolites. 2022 Nov 16;12(11):1121. doi: 10.3390/metabo12111121. Metabolites. 2022. PMID: 36422260 Free PMC article.
- Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data.Zhao Z, Tang Y, Hu Y, Zhu H, Chen X, Zhao B. Zhao Z, et al. Ann Transl Med. 2021 Sep;9(18):1482. doi: 10.21037/atm-21-4162. Ann Transl Med. 2021. PMID: 34734034 Free PMC article.
- Anti-Obesity Effect of Polygalin C Isolated from Polygala japonica Houtt. via Suppression of the Adipogenic and Lipogenic Factors in 3T3-L1 Adipocytes.Jee W, Lee SH, Ko HM, Jung JH, Chung WS, Jang HJ. Jee W, et al. Int J Mol Sci. 2021 Sep 27;22(19):10405. doi: 10.3390/ijms221910405. Int J Mol Sci. 2021. PMID: 34638751 Free PMC article.
- Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.Wong C, Lee MH, Yaow CYL, Chin YH, Goh XL, Ng CH, Lim AYL, Muthiah MD, Khoo CM. Wong C, et al. Front Endocrinol (Lausanne). 2021 Apr 9;12:609110. doi: 10.3389/fendo.2021.609110. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33897616 Free PMC article.
- Meta-Analysis
- Review
- Systematic Review
- Diabetes Mellitus, Type 2 / blood
- Diabetes Mellitus, Type 2 / drug therapy*
- Glucagon-Like Peptide 1 / analogs & derivatives*
- Glycated Hemoglobin / metabolism
- Humans
- Hypoglycemic Agents / therapeutic use*
- Randomized Controlled Trials as Topic
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Glucagon-Like Peptide 1
- Full Text Sources
- Medical
NCBI Literature Resources
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
![Analysis 2.3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-002-03.jpg)
![Analysis 2.4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-002-04.jpg)
![Analysis 2.8](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-002-08.jpg)
![Analysis 3.1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-003-01.jpg)
![Analysis 3.2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-003-02.jpg)
Analysis 3.3
Comparison 3 Exenatide 2 mg…
Analysis 3.3
Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia…
Analysis 3.4
Comparison 3 Exenatide 2 mg…
Analysis 3.4
Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 4 Weight…
Analysis 3.8
Comparison 3 Exenatide 2 mg…
Analysis 3.8
Comparison 3 Exenatide 2 mg once weekly versus DPP‐4 inhibitors, Outcome 8 Fasting…
Analysis 4.1
Comparison 4 Exenatide 2 mg…
Analysis 4.1
Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 1 HbA1c…
Analysis 4.2
Comparison 4 Exenatide 2 mg…
Analysis 4.2
Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 2 HbA1c…
Analysis 4.3
Comparison 4 Exenatide 2 mg…
Analysis 4.3
Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 3 Hypoglycaemia…
Analysis 4.4
Comparison 4 Exenatide 2 mg…
Analysis 4.4
Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 4 Hypoglycaemia…
Analysis 4.6
Comparison 4 Exenatide 2 mg…
Analysis 4.6
Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 6 Weight…
Analysis 4.9
Comparison 4 Exenatide 2 mg…
Analysis 4.9
Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 9 Fasting…
Analysis 5.1
Comparison 5 Liraglutide 0.6 mg…
Analysis 5.1
Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 1 HbA1c (%).
Analysis 5.2
Comparison 5 Liraglutide 0.6 mg…
Analysis 5.2
Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 2 HbA1c
Analysis 6.1
Comparison 6 Liraglutide 0.9 mg…
Analysis 6.1
Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 1 HbA1c (%).
Analysis 6.2
Comparison 6 Liraglutide 0.9 mg…
Analysis 6.2
Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 2 HbA1c
Analysis 7.1
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.1
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 1 HbA1c.
Analysis 7.2
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.2
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 2 HbA1c
Analysis 7.3
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.3
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 3 Hypoglycaemia.
Analysis 7.4
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.4
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 4 Weight change.
Analysis 7.6
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.6
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 6 Systolic blood pressure.
Analysis 7.7
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.7
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 7 Fasting plasma glucose (mmol/L).
Analysis 7.9
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.9
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 9 Triglycerides (mmol/L).
Analysis 7.10
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.10
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 10 Total cholesterol (mmol/L).
Analysis 7.11
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.11
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 11 HDL‐cholesterol (mmol/L).
Analysis 7.12
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.12
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 12 LDL‐cholesterol (mmol/L).
Analysis 8.1
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.1
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 1 HbA1c.
Analysis 8.2
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.2
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 2 HbA1c
Analysis 8.3
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.3
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 3 Hypoglycaemia.
Analysis 8.4
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.4
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 4 Weight change.
Analysis 8.6
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.6
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 6 Systolic blood pressure.
Analysis 8.7
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.7
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 7 Fasting plasma glucose (mmol/L).
Analysis 8.9
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.9
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 9 Triglycerides (mmol/L).
Analysis 8.10
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.10
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 10 Total cholesterol (mmol/L).
Analysis 8.11
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.11
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 11 HDL‐cholesterol (mmol/L).
Analysis 8.12
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.12
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 12 LDL‐cholesterol (mmol/L).
Analysis 9.1
Comparison 9 Liraglutide 1.2 mg…
Analysis 9.1
Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 1 HbA1c.
Analysis 9.2
Comparison 9 Liraglutide 1.2 mg…
Analysis 9.2
Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 2 Patients reaching HbA1c…
Analysis 9.3
Comparison 9 Liraglutide 1.2 mg…
Analysis 9.3
Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 3 Weight.
Analysis 9.4
Comparison 9 Liraglutide 1.2 mg…
Analysis 9.4
Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 4 Systolic blood pressure.
Analysis 10.1
Comparison 10 Liraglutide versus insulin…
Analysis 10.1
Comparison 10 Liraglutide versus insulin glargine, Outcome 1 HbA1c.
Analysis 10.2
Comparison 10 Liraglutide versus insulin…
Analysis 10.2
Comparison 10 Liraglutide versus insulin glargine, Outcome 2 HbA1c
Analysis 10.3
Comparison 10 Liraglutide versus insulin…
Analysis 10.3
Comparison 10 Liraglutide versus insulin glargine, Outcome 3 Hypoglycaemia.
Analysis 10.4
Comparison 10 Liraglutide versus insulin…
Analysis 10.4
Comparison 10 Liraglutide versus insulin glargine, Outcome 4 Weight change.
Analysis 10.6
Comparison 10 Liraglutide versus insulin…
Analysis 10.6
Comparison 10 Liraglutide versus insulin glargine, Outcome 6 Systolic blood pressure.
Analysis 10.7
Comparison 10 Liraglutide versus insulin…
Analysis 10.7
Comparison 10 Liraglutide versus insulin glargine, Outcome 7 Fasting plasma glucose (mmol/L).
Analysis 11.1
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.1
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 1 HbA1c (%).
Analysis 11.2
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.2
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 2 HbA1c
Analysis 11.3
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.3
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia (mild/moderate/overall).
Analysis 11.5
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.5
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 5 Weight change.
Analysis 11.9
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.9
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma glucose…
Analysis 12.1
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.1
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 1 HbA1c (%).
Analysis 12.2
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.2
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 2 HbA1c
Analysis 12.3
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.3
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia.
Analysis 12.5
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.5
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 5 Weight change (kg).
Analysis 12.9
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.9
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma glucose…
Analysis 13.1
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.1
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 1 HbA1c (%).
Analysis 13.2
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.2
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 2 HbA1c
Analysis 13.3
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.3
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia (mild/moderate/overall).
Analysis 13.5
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.5
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change…
Analysis 13.7
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.7
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood…
Analysis 13.9
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.9
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma…
Analysis 14.1
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.1
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 1 HbA1c (%).
Analysis 14.2
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.2
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 2 HbA1c
Analysis 14.3
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.3
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia.
Analysis 14.5
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.5
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change…
Analysis 14.7
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.7
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood…
Analysis 14.9
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.9
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma…
Analysis 15.2
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.2
Comparison 15 Lixisenatide versus placebo, Outcome 2 HbA1c
Analysis 15.3
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.3
Comparison 15 Lixisenatide versus placebo, Outcome 3 Symptomatic hypoglycaemia.
Analysis 15.4
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.4
Comparison 15 Lixisenatide versus placebo, Outcome 4 Weight change (kg).
Analysis 15.6
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.6
Comparison 15 Lixisenatide versus placebo, Outcome 6 Fasting plasma glucose (mmol/L).
Analysis 15.7
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.7
Comparison 15 Lixisenatide versus placebo, Outcome 7 Post‐prandial glucose (mmol/L).
Analysis 15.8
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.8
Comparison 15 Lixisenatide versus placebo, Outcome 8 Average self‐monitored 7‐point blood glucose (mmol/L).
Analysis 16.1
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.1
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 1 HbA1c.
Analysis 16.3
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.3
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 3 HbA1c
Analysis 16.4
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.4
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 4 Hypoglycaemia.
Analysis 16.5
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.5
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 5 Weight change.
Analysis 16.8
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.8
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 8 Systolic blood pressure.
Analysis 16.10
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.10
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 17.1
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.1
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 1 HbA1c (%).
Analysis 17.3
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.3
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 3 HbA1c
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 4 Hypoglycaemia.
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 5 Weight change (kg).
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 8 Systolic blood pressure…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 10 Fasting plasma glucose…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo, Outcome 1 HbA1c (%).
Analysis 18.3
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.3
Comparison 18 Taspoglutide versus placebo, Outcome 3 HbA1c
Analysis 18.5
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.5
Comparison 18 Taspoglutide versus placebo, Outcome 5 Hypoglycaemia.
Analysis 18.7
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.7
Comparison 18 Taspoglutide versus placebo, Outcome 7 Weight change (kg).
Analysis 18.11
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.11
Comparison 18 Taspoglutide versus placebo, Outcome 11 Fasting plasma glucose (mmol/L).
Analysis 19.4
Comparison 19 LY2189265 versus placebo,…
Analysis 19.4
Comparison 19 LY2189265 versus placebo, Outcome 4 Weight change (kg).
Analysis 19.6
Comparison 19 LY2189265 versus placebo,…
Analysis 19.6
Comparison 19 LY2189265 versus placebo, Outcome 6 Systolic blood pressure (mm Hg).
Analysis 19.7
Comparison 19 LY2189265 versus placebo,…
Analysis 19.7
Comparison 19 LY2189265 versus placebo, Outcome 7 Diastolic blood pressure (mm Hg).
Analysis 20.1
Comparison 20 GLP‐1 agonist versus…
Analysis 20.1
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 1 HbA1c.
Analysis 20.2
Comparison 20 GLP‐1 agonist versus…
Analysis 20.2
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 2 HbA1c
Analysis 20.3
Comparison 20 GLP‐1 agonist versus…
Analysis 20.3
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 3 Hypoglycaemia.
Analysis 20.5
Comparison 20 GLP‐1 agonist versus…
Analysis 20.5
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 5 Weight change.
Analysis 20.9
Comparison 20 GLP‐1 agonist versus…
Analysis 20.9
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 9 Systolic blood pressure.
Analysis 20.10
Comparison 20 GLP‐1 agonist versus…
Analysis 20.10
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 20.12
Comparison 20 GLP‐1 agonist versus…
Analysis 20.12
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 12 Triglycerides (mmol/L).
Analysis 20.13
Comparison 20 GLP‐1 agonist versus…
Analysis 20.13
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 13 Total cholesterol (mmol/L).
Analysis 20.14
Comparison 20 GLP‐1 agonist versus…
Analysis 20.14
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 14 HDL‐cholesterol (mmol/L).
Analysis 20.15
Comparison 20 GLP‐1 agonist versus…
Analysis 20.15
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 15 LDL‐cholesterol (mmol/L).
- [Efficacy of GLP-1-analogs in type 2 diabetes mellitus].Schütt M. Schütt M. Dtsch Med Wochenschr. 2013 Jan;138(1-2):15. doi: 10.1055/s-0032-1329135. Epub 2012 Dec 18. Dtsch Med Wochenschr. 2013. PMID: 23250688 German. No abstract available.
- Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Hemmingsen B, et al. Cochrane Database Syst Rev. 2017 May 10;5(5):CD012204. doi: 10.1002/14651858.CD012204.pub2. Cochrane Database Syst Rev. 2017. PMID: 28489279 Free PMC article. Review.
- Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis.Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR. Shyangdan DS, et al. BMC Endocr Disord. 2010 Dec 9;10:20. doi: 10.1186/1472-6823-10-20. BMC Endocr Disord. 2010. PMID: 21143938 Free PMC article.
- Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S. Waugh N, et al. Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Health Technol Assess. 2010. PMID: 20646668 Review.
- Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Htike ZZ, et al. Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17. Diabetes Obes Metab. 2017. PMID: 27981757 Review.
- Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.Pinelli NR, Hurren KM. Pinelli NR, et al. Ann Pharmacother. 2011 Jul;45(7-8):850-60. doi: 10.1345/aph.1Q024. Epub 2011 Jul 5. Ann Pharmacother. 2011. PMID: 21730278 Review.
- Effects of synbiotics supplementation on anthropometric and lipid profile parameters: Finding from an umbrella meta-analysis.Musazadeh V, Mohammadi Anilou M, Vajdi M, Karimi A, Sedgh Ahrabi S, Dehghan P. Musazadeh V, et al. Front Nutr. 2023 Feb 23;10:1121541. doi: 10.3389/fnut.2023.1121541. eCollection 2023. Front Nutr. 2023. PMID: 36908920 Free PMC article.
- Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients.Silva-Nunes J, Nascimento E, Louro J, Dores J, Laginha T, Gonçalves-Ferreira A, Alves M, Souto SB, Cunha N, Pina E, Duarte R, Raposo JF. Silva-Nunes J, et al. Metabolites. 2022 Nov 16;12(11):1121. doi: 10.3390/metabo12111121. Metabolites. 2022. PMID: 36422260 Free PMC article.
- Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data.Zhao Z, Tang Y, Hu Y, Zhu H, Chen X, Zhao B. Zhao Z, et al. Ann Transl Med. 2021 Sep;9(18):1482. doi: 10.21037/atm-21-4162. Ann Transl Med. 2021. PMID: 34734034 Free PMC article.
- Anti-Obesity Effect of Polygalin C Isolated from Polygala japonica Houtt. via Suppression of the Adipogenic and Lipogenic Factors in 3T3-L1 Adipocytes.Jee W, Lee SH, Ko HM, Jung JH, Chung WS, Jang HJ. Jee W, et al. Int J Mol Sci. 2021 Sep 27;22(19):10405. doi: 10.3390/ijms221910405. Int J Mol Sci. 2021. PMID: 34638751 Free PMC article.
- Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.Wong C, Lee MH, Yaow CYL, Chin YH, Goh XL, Ng CH, Lim AYL, Muthiah MD, Khoo CM. Wong C, et al. Front Endocrinol (Lausanne). 2021 Apr 9;12:609110. doi: 10.3389/fendo.2021.609110. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33897616 Free PMC article.
- Meta-Analysis
- Review
- Systematic Review
- Diabetes Mellitus, Type 2 / blood
- Diabetes Mellitus, Type 2 / drug therapy*
- Glucagon-Like Peptide 1 / analogs & derivatives*
- Glycated Hemoglobin / metabolism
- Humans
- Hypoglycemic Agents / therapeutic use*
- Randomized Controlled Trials as Topic
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Glucagon-Like Peptide 1
- Full Text Sources
- Medical
NCBI Literature Resources
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
![Analysis 3.3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-003-03.jpg)
![Analysis 3.4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-003-04.jpg)
![Analysis 3.8](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-003-08.jpg)
![Analysis 4.1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-004-01.jpg)
![Analysis 4.2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-004-02.jpg)
Analysis 4.3
Comparison 4 Exenatide 2 mg…
Analysis 4.3
Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 3 Hypoglycaemia…
Analysis 4.4
Comparison 4 Exenatide 2 mg…
Analysis 4.4
Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 4 Hypoglycaemia…
Analysis 4.6
Comparison 4 Exenatide 2 mg…
Analysis 4.6
Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 6 Weight…
Analysis 4.9
Comparison 4 Exenatide 2 mg…
Analysis 4.9
Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 9 Fasting…
Analysis 5.1
Comparison 5 Liraglutide 0.6 mg…
Analysis 5.1
Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 1 HbA1c (%).
Analysis 5.2
Comparison 5 Liraglutide 0.6 mg…
Analysis 5.2
Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 2 HbA1c
Analysis 6.1
Comparison 6 Liraglutide 0.9 mg…
Analysis 6.1
Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 1 HbA1c (%).
Analysis 6.2
Comparison 6 Liraglutide 0.9 mg…
Analysis 6.2
Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 2 HbA1c
Analysis 7.1
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.1
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 1 HbA1c.
Analysis 7.2
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.2
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 2 HbA1c
Analysis 7.3
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.3
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 3 Hypoglycaemia.
Analysis 7.4
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.4
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 4 Weight change.
Analysis 7.6
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.6
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 6 Systolic blood pressure.
Analysis 7.7
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.7
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 7 Fasting plasma glucose (mmol/L).
Analysis 7.9
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.9
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 9 Triglycerides (mmol/L).
Analysis 7.10
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.10
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 10 Total cholesterol (mmol/L).
Analysis 7.11
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.11
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 11 HDL‐cholesterol (mmol/L).
Analysis 7.12
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.12
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 12 LDL‐cholesterol (mmol/L).
Analysis 8.1
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.1
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 1 HbA1c.
Analysis 8.2
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.2
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 2 HbA1c
Analysis 8.3
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.3
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 3 Hypoglycaemia.
Analysis 8.4
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.4
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 4 Weight change.
Analysis 8.6
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.6
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 6 Systolic blood pressure.
Analysis 8.7
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.7
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 7 Fasting plasma glucose (mmol/L).
Analysis 8.9
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.9
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 9 Triglycerides (mmol/L).
Analysis 8.10
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.10
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 10 Total cholesterol (mmol/L).
Analysis 8.11
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.11
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 11 HDL‐cholesterol (mmol/L).
Analysis 8.12
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.12
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 12 LDL‐cholesterol (mmol/L).
Analysis 9.1
Comparison 9 Liraglutide 1.2 mg…
Analysis 9.1
Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 1 HbA1c.
Analysis 9.2
Comparison 9 Liraglutide 1.2 mg…
Analysis 9.2
Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 2 Patients reaching HbA1c…
Analysis 9.3
Comparison 9 Liraglutide 1.2 mg…
Analysis 9.3
Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 3 Weight.
Analysis 9.4
Comparison 9 Liraglutide 1.2 mg…
Analysis 9.4
Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 4 Systolic blood pressure.
Analysis 10.1
Comparison 10 Liraglutide versus insulin…
Analysis 10.1
Comparison 10 Liraglutide versus insulin glargine, Outcome 1 HbA1c.
Analysis 10.2
Comparison 10 Liraglutide versus insulin…
Analysis 10.2
Comparison 10 Liraglutide versus insulin glargine, Outcome 2 HbA1c
Analysis 10.3
Comparison 10 Liraglutide versus insulin…
Analysis 10.3
Comparison 10 Liraglutide versus insulin glargine, Outcome 3 Hypoglycaemia.
Analysis 10.4
Comparison 10 Liraglutide versus insulin…
Analysis 10.4
Comparison 10 Liraglutide versus insulin glargine, Outcome 4 Weight change.
Analysis 10.6
Comparison 10 Liraglutide versus insulin…
Analysis 10.6
Comparison 10 Liraglutide versus insulin glargine, Outcome 6 Systolic blood pressure.
Analysis 10.7
Comparison 10 Liraglutide versus insulin…
Analysis 10.7
Comparison 10 Liraglutide versus insulin glargine, Outcome 7 Fasting plasma glucose (mmol/L).
Analysis 11.1
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.1
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 1 HbA1c (%).
Analysis 11.2
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.2
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 2 HbA1c
Analysis 11.3
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.3
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia (mild/moderate/overall).
Analysis 11.5
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.5
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 5 Weight change.
Analysis 11.9
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.9
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma glucose…
Analysis 12.1
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.1
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 1 HbA1c (%).
Analysis 12.2
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.2
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 2 HbA1c
Analysis 12.3
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.3
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia.
Analysis 12.5
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.5
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 5 Weight change (kg).
Analysis 12.9
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.9
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma glucose…
Analysis 13.1
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.1
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 1 HbA1c (%).
Analysis 13.2
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.2
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 2 HbA1c
Analysis 13.3
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.3
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia (mild/moderate/overall).
Analysis 13.5
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.5
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change…
Analysis 13.7
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.7
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood…
Analysis 13.9
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.9
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma…
Analysis 14.1
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.1
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 1 HbA1c (%).
Analysis 14.2
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.2
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 2 HbA1c
Analysis 14.3
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.3
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia.
Analysis 14.5
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.5
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change…
Analysis 14.7
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.7
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood…
Analysis 14.9
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.9
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma…
Analysis 15.2
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.2
Comparison 15 Lixisenatide versus placebo, Outcome 2 HbA1c
Analysis 15.3
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.3
Comparison 15 Lixisenatide versus placebo, Outcome 3 Symptomatic hypoglycaemia.
Analysis 15.4
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.4
Comparison 15 Lixisenatide versus placebo, Outcome 4 Weight change (kg).
Analysis 15.6
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.6
Comparison 15 Lixisenatide versus placebo, Outcome 6 Fasting plasma glucose (mmol/L).
Analysis 15.7
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.7
Comparison 15 Lixisenatide versus placebo, Outcome 7 Post‐prandial glucose (mmol/L).
Analysis 15.8
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.8
Comparison 15 Lixisenatide versus placebo, Outcome 8 Average self‐monitored 7‐point blood glucose (mmol/L).
Analysis 16.1
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.1
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 1 HbA1c.
Analysis 16.3
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.3
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 3 HbA1c
Analysis 16.4
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.4
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 4 Hypoglycaemia.
Analysis 16.5
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.5
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 5 Weight change.
Analysis 16.8
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.8
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 8 Systolic blood pressure.
Analysis 16.10
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.10
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 17.1
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.1
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 1 HbA1c (%).
Analysis 17.3
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.3
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 3 HbA1c
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 4 Hypoglycaemia.
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 5 Weight change (kg).
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 8 Systolic blood pressure…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 10 Fasting plasma glucose…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo, Outcome 1 HbA1c (%).
Analysis 18.3
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.3
Comparison 18 Taspoglutide versus placebo, Outcome 3 HbA1c
Analysis 18.5
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.5
Comparison 18 Taspoglutide versus placebo, Outcome 5 Hypoglycaemia.
Analysis 18.7
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.7
Comparison 18 Taspoglutide versus placebo, Outcome 7 Weight change (kg).
Analysis 18.11
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.11
Comparison 18 Taspoglutide versus placebo, Outcome 11 Fasting plasma glucose (mmol/L).
Analysis 19.4
Comparison 19 LY2189265 versus placebo,…
Analysis 19.4
Comparison 19 LY2189265 versus placebo, Outcome 4 Weight change (kg).
Analysis 19.6
Comparison 19 LY2189265 versus placebo,…
Analysis 19.6
Comparison 19 LY2189265 versus placebo, Outcome 6 Systolic blood pressure (mm Hg).
Analysis 19.7
Comparison 19 LY2189265 versus placebo,…
Analysis 19.7
Comparison 19 LY2189265 versus placebo, Outcome 7 Diastolic blood pressure (mm Hg).
Analysis 20.1
Comparison 20 GLP‐1 agonist versus…
Analysis 20.1
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 1 HbA1c.
Analysis 20.2
Comparison 20 GLP‐1 agonist versus…
Analysis 20.2
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 2 HbA1c
Analysis 20.3
Comparison 20 GLP‐1 agonist versus…
Analysis 20.3
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 3 Hypoglycaemia.
Analysis 20.5
Comparison 20 GLP‐1 agonist versus…
Analysis 20.5
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 5 Weight change.
Analysis 20.9
Comparison 20 GLP‐1 agonist versus…
Analysis 20.9
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 9 Systolic blood pressure.
Analysis 20.10
Comparison 20 GLP‐1 agonist versus…
Analysis 20.10
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 20.12
Comparison 20 GLP‐1 agonist versus…
Analysis 20.12
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 12 Triglycerides (mmol/L).
Analysis 20.13
Comparison 20 GLP‐1 agonist versus…
Analysis 20.13
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 13 Total cholesterol (mmol/L).
Analysis 20.14
Comparison 20 GLP‐1 agonist versus…
Analysis 20.14
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 14 HDL‐cholesterol (mmol/L).
Analysis 20.15
Comparison 20 GLP‐1 agonist versus…
Analysis 20.15
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 15 LDL‐cholesterol (mmol/L).
- [Efficacy of GLP-1-analogs in type 2 diabetes mellitus].Schütt M. Schütt M. Dtsch Med Wochenschr. 2013 Jan;138(1-2):15. doi: 10.1055/s-0032-1329135. Epub 2012 Dec 18. Dtsch Med Wochenschr. 2013. PMID: 23250688 German. No abstract available.
- Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Hemmingsen B, et al. Cochrane Database Syst Rev. 2017 May 10;5(5):CD012204. doi: 10.1002/14651858.CD012204.pub2. Cochrane Database Syst Rev. 2017. PMID: 28489279 Free PMC article. Review.
- Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis.Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR. Shyangdan DS, et al. BMC Endocr Disord. 2010 Dec 9;10:20. doi: 10.1186/1472-6823-10-20. BMC Endocr Disord. 2010. PMID: 21143938 Free PMC article.
- Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S. Waugh N, et al. Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Health Technol Assess. 2010. PMID: 20646668 Review.
- Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Htike ZZ, et al. Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17. Diabetes Obes Metab. 2017. PMID: 27981757 Review.
- Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.Pinelli NR, Hurren KM. Pinelli NR, et al. Ann Pharmacother. 2011 Jul;45(7-8):850-60. doi: 10.1345/aph.1Q024. Epub 2011 Jul 5. Ann Pharmacother. 2011. PMID: 21730278 Review.
- Effects of synbiotics supplementation on anthropometric and lipid profile parameters: Finding from an umbrella meta-analysis.Musazadeh V, Mohammadi Anilou M, Vajdi M, Karimi A, Sedgh Ahrabi S, Dehghan P. Musazadeh V, et al. Front Nutr. 2023 Feb 23;10:1121541. doi: 10.3389/fnut.2023.1121541. eCollection 2023. Front Nutr. 2023. PMID: 36908920 Free PMC article.
- Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients.Silva-Nunes J, Nascimento E, Louro J, Dores J, Laginha T, Gonçalves-Ferreira A, Alves M, Souto SB, Cunha N, Pina E, Duarte R, Raposo JF. Silva-Nunes J, et al. Metabolites. 2022 Nov 16;12(11):1121. doi: 10.3390/metabo12111121. Metabolites. 2022. PMID: 36422260 Free PMC article.
- Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data.Zhao Z, Tang Y, Hu Y, Zhu H, Chen X, Zhao B. Zhao Z, et al. Ann Transl Med. 2021 Sep;9(18):1482. doi: 10.21037/atm-21-4162. Ann Transl Med. 2021. PMID: 34734034 Free PMC article.
- Anti-Obesity Effect of Polygalin C Isolated from Polygala japonica Houtt. via Suppression of the Adipogenic and Lipogenic Factors in 3T3-L1 Adipocytes.Jee W, Lee SH, Ko HM, Jung JH, Chung WS, Jang HJ. Jee W, et al. Int J Mol Sci. 2021 Sep 27;22(19):10405. doi: 10.3390/ijms221910405. Int J Mol Sci. 2021. PMID: 34638751 Free PMC article.
- Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.Wong C, Lee MH, Yaow CYL, Chin YH, Goh XL, Ng CH, Lim AYL, Muthiah MD, Khoo CM. Wong C, et al. Front Endocrinol (Lausanne). 2021 Apr 9;12:609110. doi: 10.3389/fendo.2021.609110. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33897616 Free PMC article.
- Meta-Analysis
- Review
- Systematic Review
- Diabetes Mellitus, Type 2 / blood
- Diabetes Mellitus, Type 2 / drug therapy*
- Glucagon-Like Peptide 1 / analogs & derivatives*
- Glycated Hemoglobin / metabolism
- Humans
- Hypoglycemic Agents / therapeutic use*
- Randomized Controlled Trials as Topic
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Glucagon-Like Peptide 1
- Full Text Sources
- Medical
NCBI Literature Resources
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
![Analysis 4.3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-004-03.jpg)
![Analysis 4.4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-004-04.jpg)
![Analysis 4.6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-004-06.jpg)
![Analysis 4.9](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-004-09.jpg)
![Analysis 5.1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-005-01.jpg)
![Analysis 5.2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-005-02.jpg)
Analysis 6.1
Comparison 6 Liraglutide 0.9 mg…
Analysis 6.1
Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 1 HbA1c (%).
Analysis 6.2
Comparison 6 Liraglutide 0.9 mg…
Analysis 6.2
Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 2 HbA1c
Analysis 7.1
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.1
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 1 HbA1c.
Analysis 7.2
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.2
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 2 HbA1c
Analysis 7.3
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.3
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 3 Hypoglycaemia.
Analysis 7.4
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.4
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 4 Weight change.
Analysis 7.6
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.6
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 6 Systolic blood pressure.
Analysis 7.7
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.7
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 7 Fasting plasma glucose (mmol/L).
Analysis 7.9
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.9
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 9 Triglycerides (mmol/L).
Analysis 7.10
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.10
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 10 Total cholesterol (mmol/L).
Analysis 7.11
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.11
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 11 HDL‐cholesterol (mmol/L).
Analysis 7.12
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.12
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 12 LDL‐cholesterol (mmol/L).
Analysis 8.1
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.1
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 1 HbA1c.
Analysis 8.2
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.2
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 2 HbA1c
Analysis 8.3
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.3
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 3 Hypoglycaemia.
Analysis 8.4
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.4
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 4 Weight change.
Analysis 8.6
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.6
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 6 Systolic blood pressure.
Analysis 8.7
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.7
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 7 Fasting plasma glucose (mmol/L).
Analysis 8.9
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.9
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 9 Triglycerides (mmol/L).
Analysis 8.10
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.10
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 10 Total cholesterol (mmol/L).
Analysis 8.11
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.11
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 11 HDL‐cholesterol (mmol/L).
Analysis 8.12
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.12
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 12 LDL‐cholesterol (mmol/L).
Analysis 9.1
Comparison 9 Liraglutide 1.2 mg…
Analysis 9.1
Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 1 HbA1c.
Analysis 9.2
Comparison 9 Liraglutide 1.2 mg…
Analysis 9.2
Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 2 Patients reaching HbA1c…
Analysis 9.3
Comparison 9 Liraglutide 1.2 mg…
Analysis 9.3
Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 3 Weight.
Analysis 9.4
Comparison 9 Liraglutide 1.2 mg…
Analysis 9.4
Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 4 Systolic blood pressure.
Analysis 10.1
Comparison 10 Liraglutide versus insulin…
Analysis 10.1
Comparison 10 Liraglutide versus insulin glargine, Outcome 1 HbA1c.
Analysis 10.2
Comparison 10 Liraglutide versus insulin…
Analysis 10.2
Comparison 10 Liraglutide versus insulin glargine, Outcome 2 HbA1c
Analysis 10.3
Comparison 10 Liraglutide versus insulin…
Analysis 10.3
Comparison 10 Liraglutide versus insulin glargine, Outcome 3 Hypoglycaemia.
Analysis 10.4
Comparison 10 Liraglutide versus insulin…
Analysis 10.4
Comparison 10 Liraglutide versus insulin glargine, Outcome 4 Weight change.
Analysis 10.6
Comparison 10 Liraglutide versus insulin…
Analysis 10.6
Comparison 10 Liraglutide versus insulin glargine, Outcome 6 Systolic blood pressure.
Analysis 10.7
Comparison 10 Liraglutide versus insulin…
Analysis 10.7
Comparison 10 Liraglutide versus insulin glargine, Outcome 7 Fasting plasma glucose (mmol/L).
Analysis 11.1
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.1
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 1 HbA1c (%).
Analysis 11.2
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.2
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 2 HbA1c
Analysis 11.3
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.3
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia (mild/moderate/overall).
Analysis 11.5
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.5
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 5 Weight change.
Analysis 11.9
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.9
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma glucose…
Analysis 12.1
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.1
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 1 HbA1c (%).
Analysis 12.2
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.2
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 2 HbA1c
Analysis 12.3
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.3
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia.
Analysis 12.5
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.5
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 5 Weight change (kg).
Analysis 12.9
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.9
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma glucose…
Analysis 13.1
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.1
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 1 HbA1c (%).
Analysis 13.2
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.2
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 2 HbA1c
Analysis 13.3
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.3
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia (mild/moderate/overall).
Analysis 13.5
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.5
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change…
Analysis 13.7
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.7
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood…
Analysis 13.9
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.9
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma…
Analysis 14.1
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.1
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 1 HbA1c (%).
Analysis 14.2
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.2
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 2 HbA1c
Analysis 14.3
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.3
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia.
Analysis 14.5
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.5
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change…
Analysis 14.7
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.7
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood…
Analysis 14.9
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.9
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma…
Analysis 15.2
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.2
Comparison 15 Lixisenatide versus placebo, Outcome 2 HbA1c
Analysis 15.3
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.3
Comparison 15 Lixisenatide versus placebo, Outcome 3 Symptomatic hypoglycaemia.
Analysis 15.4
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.4
Comparison 15 Lixisenatide versus placebo, Outcome 4 Weight change (kg).
Analysis 15.6
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.6
Comparison 15 Lixisenatide versus placebo, Outcome 6 Fasting plasma glucose (mmol/L).
Analysis 15.7
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.7
Comparison 15 Lixisenatide versus placebo, Outcome 7 Post‐prandial glucose (mmol/L).
Analysis 15.8
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.8
Comparison 15 Lixisenatide versus placebo, Outcome 8 Average self‐monitored 7‐point blood glucose (mmol/L).
Analysis 16.1
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.1
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 1 HbA1c.
Analysis 16.3
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.3
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 3 HbA1c
Analysis 16.4
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.4
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 4 Hypoglycaemia.
Analysis 16.5
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.5
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 5 Weight change.
Analysis 16.8
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.8
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 8 Systolic blood pressure.
Analysis 16.10
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.10
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 17.1
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.1
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 1 HbA1c (%).
Analysis 17.3
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.3
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 3 HbA1c
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 4 Hypoglycaemia.
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 5 Weight change (kg).
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 8 Systolic blood pressure…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 10 Fasting plasma glucose…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo, Outcome 1 HbA1c (%).
Analysis 18.3
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.3
Comparison 18 Taspoglutide versus placebo, Outcome 3 HbA1c
Analysis 18.5
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.5
Comparison 18 Taspoglutide versus placebo, Outcome 5 Hypoglycaemia.
Analysis 18.7
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.7
Comparison 18 Taspoglutide versus placebo, Outcome 7 Weight change (kg).
Analysis 18.11
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.11
Comparison 18 Taspoglutide versus placebo, Outcome 11 Fasting plasma glucose (mmol/L).
Analysis 19.4
Comparison 19 LY2189265 versus placebo,…
Analysis 19.4
Comparison 19 LY2189265 versus placebo, Outcome 4 Weight change (kg).
Analysis 19.6
Comparison 19 LY2189265 versus placebo,…
Analysis 19.6
Comparison 19 LY2189265 versus placebo, Outcome 6 Systolic blood pressure (mm Hg).
Analysis 19.7
Comparison 19 LY2189265 versus placebo,…
Analysis 19.7
Comparison 19 LY2189265 versus placebo, Outcome 7 Diastolic blood pressure (mm Hg).
Analysis 20.1
Comparison 20 GLP‐1 agonist versus…
Analysis 20.1
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 1 HbA1c.
Analysis 20.2
Comparison 20 GLP‐1 agonist versus…
Analysis 20.2
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 2 HbA1c
Analysis 20.3
Comparison 20 GLP‐1 agonist versus…
Analysis 20.3
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 3 Hypoglycaemia.
Analysis 20.5
Comparison 20 GLP‐1 agonist versus…
Analysis 20.5
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 5 Weight change.
Analysis 20.9
Comparison 20 GLP‐1 agonist versus…
Analysis 20.9
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 9 Systolic blood pressure.
Analysis 20.10
Comparison 20 GLP‐1 agonist versus…
Analysis 20.10
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 20.12
Comparison 20 GLP‐1 agonist versus…
Analysis 20.12
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 12 Triglycerides (mmol/L).
Analysis 20.13
Comparison 20 GLP‐1 agonist versus…
Analysis 20.13
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 13 Total cholesterol (mmol/L).
Analysis 20.14
Comparison 20 GLP‐1 agonist versus…
Analysis 20.14
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 14 HDL‐cholesterol (mmol/L).
Analysis 20.15
Comparison 20 GLP‐1 agonist versus…
Analysis 20.15
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 15 LDL‐cholesterol (mmol/L).
- [Efficacy of GLP-1-analogs in type 2 diabetes mellitus].Schütt M. Schütt M. Dtsch Med Wochenschr. 2013 Jan;138(1-2):15. doi: 10.1055/s-0032-1329135. Epub 2012 Dec 18. Dtsch Med Wochenschr. 2013. PMID: 23250688 German. No abstract available.
- Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Hemmingsen B, et al. Cochrane Database Syst Rev. 2017 May 10;5(5):CD012204. doi: 10.1002/14651858.CD012204.pub2. Cochrane Database Syst Rev. 2017. PMID: 28489279 Free PMC article. Review.
- Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis.Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR. Shyangdan DS, et al. BMC Endocr Disord. 2010 Dec 9;10:20. doi: 10.1186/1472-6823-10-20. BMC Endocr Disord. 2010. PMID: 21143938 Free PMC article.
- Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S. Waugh N, et al. Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Health Technol Assess. 2010. PMID: 20646668 Review.
- Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Htike ZZ, et al. Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17. Diabetes Obes Metab. 2017. PMID: 27981757 Review.
- Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.Pinelli NR, Hurren KM. Pinelli NR, et al. Ann Pharmacother. 2011 Jul;45(7-8):850-60. doi: 10.1345/aph.1Q024. Epub 2011 Jul 5. Ann Pharmacother. 2011. PMID: 21730278 Review.
- Effects of synbiotics supplementation on anthropometric and lipid profile parameters: Finding from an umbrella meta-analysis.Musazadeh V, Mohammadi Anilou M, Vajdi M, Karimi A, Sedgh Ahrabi S, Dehghan P. Musazadeh V, et al. Front Nutr. 2023 Feb 23;10:1121541. doi: 10.3389/fnut.2023.1121541. eCollection 2023. Front Nutr. 2023. PMID: 36908920 Free PMC article.
- Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients.Silva-Nunes J, Nascimento E, Louro J, Dores J, Laginha T, Gonçalves-Ferreira A, Alves M, Souto SB, Cunha N, Pina E, Duarte R, Raposo JF. Silva-Nunes J, et al. Metabolites. 2022 Nov 16;12(11):1121. doi: 10.3390/metabo12111121. Metabolites. 2022. PMID: 36422260 Free PMC article.
- Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data.Zhao Z, Tang Y, Hu Y, Zhu H, Chen X, Zhao B. Zhao Z, et al. Ann Transl Med. 2021 Sep;9(18):1482. doi: 10.21037/atm-21-4162. Ann Transl Med. 2021. PMID: 34734034 Free PMC article.
- Anti-Obesity Effect of Polygalin C Isolated from Polygala japonica Houtt. via Suppression of the Adipogenic and Lipogenic Factors in 3T3-L1 Adipocytes.Jee W, Lee SH, Ko HM, Jung JH, Chung WS, Jang HJ. Jee W, et al. Int J Mol Sci. 2021 Sep 27;22(19):10405. doi: 10.3390/ijms221910405. Int J Mol Sci. 2021. PMID: 34638751 Free PMC article.
- Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.Wong C, Lee MH, Yaow CYL, Chin YH, Goh XL, Ng CH, Lim AYL, Muthiah MD, Khoo CM. Wong C, et al. Front Endocrinol (Lausanne). 2021 Apr 9;12:609110. doi: 10.3389/fendo.2021.609110. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33897616 Free PMC article.
- Meta-Analysis
- Review
- Systematic Review
- Diabetes Mellitus, Type 2 / blood
- Diabetes Mellitus, Type 2 / drug therapy*
- Glucagon-Like Peptide 1 / analogs & derivatives*
- Glycated Hemoglobin / metabolism
- Humans
- Hypoglycemic Agents / therapeutic use*
- Randomized Controlled Trials as Topic
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Glucagon-Like Peptide 1
- Full Text Sources
- Medical
NCBI Literature Resources
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
![Analysis 6.1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-006-01.jpg)
![Analysis 6.2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-006-02.jpg)
Analysis 7.1
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.1
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 1 HbA1c.
Analysis 7.2
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.2
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 2 HbA1c
Analysis 7.3
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.3
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 3 Hypoglycaemia.
Analysis 7.4
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.4
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 4 Weight change.
Analysis 7.6
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.6
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 6 Systolic blood pressure.
Analysis 7.7
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.7
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 7 Fasting plasma glucose (mmol/L).
Analysis 7.9
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.9
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 9 Triglycerides (mmol/L).
Analysis 7.10
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.10
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 10 Total cholesterol (mmol/L).
Analysis 7.11
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.11
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 11 HDL‐cholesterol (mmol/L).
Analysis 7.12
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.12
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 12 LDL‐cholesterol (mmol/L).
Analysis 8.1
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.1
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 1 HbA1c.
Analysis 8.2
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.2
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 2 HbA1c
Analysis 8.3
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.3
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 3 Hypoglycaemia.
Analysis 8.4
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.4
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 4 Weight change.
Analysis 8.6
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.6
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 6 Systolic blood pressure.
Analysis 8.7
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.7
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 7 Fasting plasma glucose (mmol/L).
Analysis 8.9
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.9
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 9 Triglycerides (mmol/L).
Analysis 8.10
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.10
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 10 Total cholesterol (mmol/L).
Analysis 8.11
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.11
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 11 HDL‐cholesterol (mmol/L).
Analysis 8.12
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.12
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 12 LDL‐cholesterol (mmol/L).
Analysis 9.1
Comparison 9 Liraglutide 1.2 mg…
Analysis 9.1
Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 1 HbA1c.
Analysis 9.2
Comparison 9 Liraglutide 1.2 mg…
Analysis 9.2
Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 2 Patients reaching HbA1c…
Analysis 9.3
Comparison 9 Liraglutide 1.2 mg…
Analysis 9.3
Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 3 Weight.
Analysis 9.4
Comparison 9 Liraglutide 1.2 mg…
Analysis 9.4
Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 4 Systolic blood pressure.
Analysis 10.1
Comparison 10 Liraglutide versus insulin…
Analysis 10.1
Comparison 10 Liraglutide versus insulin glargine, Outcome 1 HbA1c.
Analysis 10.2
Comparison 10 Liraglutide versus insulin…
Analysis 10.2
Comparison 10 Liraglutide versus insulin glargine, Outcome 2 HbA1c
Analysis 10.3
Comparison 10 Liraglutide versus insulin…
Analysis 10.3
Comparison 10 Liraglutide versus insulin glargine, Outcome 3 Hypoglycaemia.
Analysis 10.4
Comparison 10 Liraglutide versus insulin…
Analysis 10.4
Comparison 10 Liraglutide versus insulin glargine, Outcome 4 Weight change.
Analysis 10.6
Comparison 10 Liraglutide versus insulin…
Analysis 10.6
Comparison 10 Liraglutide versus insulin glargine, Outcome 6 Systolic blood pressure.
Analysis 10.7
Comparison 10 Liraglutide versus insulin…
Analysis 10.7
Comparison 10 Liraglutide versus insulin glargine, Outcome 7 Fasting plasma glucose (mmol/L).
Analysis 11.1
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.1
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 1 HbA1c (%).
Analysis 11.2
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.2
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 2 HbA1c
Analysis 11.3
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.3
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia (mild/moderate/overall).
Analysis 11.5
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.5
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 5 Weight change.
Analysis 11.9
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.9
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma glucose…
Analysis 12.1
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.1
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 1 HbA1c (%).
Analysis 12.2
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.2
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 2 HbA1c
Analysis 12.3
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.3
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia.
Analysis 12.5
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.5
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 5 Weight change (kg).
Analysis 12.9
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.9
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma glucose…
Analysis 13.1
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.1
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 1 HbA1c (%).
Analysis 13.2
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.2
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 2 HbA1c
Analysis 13.3
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.3
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia (mild/moderate/overall).
Analysis 13.5
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.5
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change…
Analysis 13.7
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.7
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood…
Analysis 13.9
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.9
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma…
Analysis 14.1
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.1
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 1 HbA1c (%).
Analysis 14.2
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.2
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 2 HbA1c
Analysis 14.3
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.3
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia.
Analysis 14.5
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.5
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change…
Analysis 14.7
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.7
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood…
Analysis 14.9
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.9
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma…
Analysis 15.2
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.2
Comparison 15 Lixisenatide versus placebo, Outcome 2 HbA1c
Analysis 15.3
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.3
Comparison 15 Lixisenatide versus placebo, Outcome 3 Symptomatic hypoglycaemia.
Analysis 15.4
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.4
Comparison 15 Lixisenatide versus placebo, Outcome 4 Weight change (kg).
Analysis 15.6
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.6
Comparison 15 Lixisenatide versus placebo, Outcome 6 Fasting plasma glucose (mmol/L).
Analysis 15.7
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.7
Comparison 15 Lixisenatide versus placebo, Outcome 7 Post‐prandial glucose (mmol/L).
Analysis 15.8
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.8
Comparison 15 Lixisenatide versus placebo, Outcome 8 Average self‐monitored 7‐point blood glucose (mmol/L).
Analysis 16.1
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.1
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 1 HbA1c.
Analysis 16.3
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.3
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 3 HbA1c
Analysis 16.4
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.4
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 4 Hypoglycaemia.
Analysis 16.5
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.5
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 5 Weight change.
Analysis 16.8
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.8
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 8 Systolic blood pressure.
Analysis 16.10
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.10
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 17.1
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.1
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 1 HbA1c (%).
Analysis 17.3
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.3
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 3 HbA1c
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 4 Hypoglycaemia.
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 5 Weight change (kg).
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 8 Systolic blood pressure…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 10 Fasting plasma glucose…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo, Outcome 1 HbA1c (%).
Analysis 18.3
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.3
Comparison 18 Taspoglutide versus placebo, Outcome 3 HbA1c
Analysis 18.5
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.5
Comparison 18 Taspoglutide versus placebo, Outcome 5 Hypoglycaemia.
Analysis 18.7
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.7
Comparison 18 Taspoglutide versus placebo, Outcome 7 Weight change (kg).
Analysis 18.11
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.11
Comparison 18 Taspoglutide versus placebo, Outcome 11 Fasting plasma glucose (mmol/L).
Analysis 19.4
Comparison 19 LY2189265 versus placebo,…
Analysis 19.4
Comparison 19 LY2189265 versus placebo, Outcome 4 Weight change (kg).
Analysis 19.6
Comparison 19 LY2189265 versus placebo,…
Analysis 19.6
Comparison 19 LY2189265 versus placebo, Outcome 6 Systolic blood pressure (mm Hg).
Analysis 19.7
Comparison 19 LY2189265 versus placebo,…
Analysis 19.7
Comparison 19 LY2189265 versus placebo, Outcome 7 Diastolic blood pressure (mm Hg).
Analysis 20.1
Comparison 20 GLP‐1 agonist versus…
Analysis 20.1
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 1 HbA1c.
Analysis 20.2
Comparison 20 GLP‐1 agonist versus…
Analysis 20.2
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 2 HbA1c
Analysis 20.3
Comparison 20 GLP‐1 agonist versus…
Analysis 20.3
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 3 Hypoglycaemia.
Analysis 20.5
Comparison 20 GLP‐1 agonist versus…
Analysis 20.5
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 5 Weight change.
Analysis 20.9
Comparison 20 GLP‐1 agonist versus…
Analysis 20.9
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 9 Systolic blood pressure.
Analysis 20.10
Comparison 20 GLP‐1 agonist versus…
Analysis 20.10
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 20.12
Comparison 20 GLP‐1 agonist versus…
Analysis 20.12
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 12 Triglycerides (mmol/L).
Analysis 20.13
Comparison 20 GLP‐1 agonist versus…
Analysis 20.13
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 13 Total cholesterol (mmol/L).
Analysis 20.14
Comparison 20 GLP‐1 agonist versus…
Analysis 20.14
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 14 HDL‐cholesterol (mmol/L).
Analysis 20.15
Comparison 20 GLP‐1 agonist versus…
Analysis 20.15
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 15 LDL‐cholesterol (mmol/L).
- [Efficacy of GLP-1-analogs in type 2 diabetes mellitus].Schütt M. Schütt M. Dtsch Med Wochenschr. 2013 Jan;138(1-2):15. doi: 10.1055/s-0032-1329135. Epub 2012 Dec 18. Dtsch Med Wochenschr. 2013. PMID: 23250688 German. No abstract available.
- Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Hemmingsen B, et al. Cochrane Database Syst Rev. 2017 May 10;5(5):CD012204. doi: 10.1002/14651858.CD012204.pub2. Cochrane Database Syst Rev. 2017. PMID: 28489279 Free PMC article. Review.
- Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis.Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR. Shyangdan DS, et al. BMC Endocr Disord. 2010 Dec 9;10:20. doi: 10.1186/1472-6823-10-20. BMC Endocr Disord. 2010. PMID: 21143938 Free PMC article.
- Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S. Waugh N, et al. Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Health Technol Assess. 2010. PMID: 20646668 Review.
- Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Htike ZZ, et al. Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17. Diabetes Obes Metab. 2017. PMID: 27981757 Review.
- Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.Pinelli NR, Hurren KM. Pinelli NR, et al. Ann Pharmacother. 2011 Jul;45(7-8):850-60. doi: 10.1345/aph.1Q024. Epub 2011 Jul 5. Ann Pharmacother. 2011. PMID: 21730278 Review.
- Effects of synbiotics supplementation on anthropometric and lipid profile parameters: Finding from an umbrella meta-analysis.Musazadeh V, Mohammadi Anilou M, Vajdi M, Karimi A, Sedgh Ahrabi S, Dehghan P. Musazadeh V, et al. Front Nutr. 2023 Feb 23;10:1121541. doi: 10.3389/fnut.2023.1121541. eCollection 2023. Front Nutr. 2023. PMID: 36908920 Free PMC article.
- Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients.Silva-Nunes J, Nascimento E, Louro J, Dores J, Laginha T, Gonçalves-Ferreira A, Alves M, Souto SB, Cunha N, Pina E, Duarte R, Raposo JF. Silva-Nunes J, et al. Metabolites. 2022 Nov 16;12(11):1121. doi: 10.3390/metabo12111121. Metabolites. 2022. PMID: 36422260 Free PMC article.
- Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data.Zhao Z, Tang Y, Hu Y, Zhu H, Chen X, Zhao B. Zhao Z, et al. Ann Transl Med. 2021 Sep;9(18):1482. doi: 10.21037/atm-21-4162. Ann Transl Med. 2021. PMID: 34734034 Free PMC article.
- Anti-Obesity Effect of Polygalin C Isolated from Polygala japonica Houtt. via Suppression of the Adipogenic and Lipogenic Factors in 3T3-L1 Adipocytes.Jee W, Lee SH, Ko HM, Jung JH, Chung WS, Jang HJ. Jee W, et al. Int J Mol Sci. 2021 Sep 27;22(19):10405. doi: 10.3390/ijms221910405. Int J Mol Sci. 2021. PMID: 34638751 Free PMC article.
- Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.Wong C, Lee MH, Yaow CYL, Chin YH, Goh XL, Ng CH, Lim AYL, Muthiah MD, Khoo CM. Wong C, et al. Front Endocrinol (Lausanne). 2021 Apr 9;12:609110. doi: 10.3389/fendo.2021.609110. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33897616 Free PMC article.
- Meta-Analysis
- Review
- Systematic Review
- Diabetes Mellitus, Type 2 / blood
- Diabetes Mellitus, Type 2 / drug therapy*
- Glucagon-Like Peptide 1 / analogs & derivatives*
- Glycated Hemoglobin / metabolism
- Humans
- Hypoglycemic Agents / therapeutic use*
- Randomized Controlled Trials as Topic
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Glucagon-Like Peptide 1
- Full Text Sources
- Medical
NCBI Literature Resources
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
![Analysis 7.1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-007-01.jpg)
![Analysis 7.2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-007-02.jpg)
Analysis 7.3
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.3
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 3 Hypoglycaemia.
Analysis 7.4
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.4
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 4 Weight change.
Analysis 7.6
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.6
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 6 Systolic blood pressure.
Analysis 7.7
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.7
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 7 Fasting plasma glucose (mmol/L).
Analysis 7.9
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.9
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 9 Triglycerides (mmol/L).
Analysis 7.10
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.10
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 10 Total cholesterol (mmol/L).
Analysis 7.11
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.11
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 11 HDL‐cholesterol (mmol/L).
Analysis 7.12
Comparison 7 Liraglutide 1.2 mg…
Analysis 7.12
Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 12 LDL‐cholesterol (mmol/L).
Analysis 8.1
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.1
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 1 HbA1c.
Analysis 8.2
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.2
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 2 HbA1c
Analysis 8.3
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.3
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 3 Hypoglycaemia.
Analysis 8.4
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.4
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 4 Weight change.
Analysis 8.6
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.6
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 6 Systolic blood pressure.
Analysis 8.7
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.7
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 7 Fasting plasma glucose (mmol/L).
Analysis 8.9
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.9
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 9 Triglycerides (mmol/L).
Analysis 8.10
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.10
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 10 Total cholesterol (mmol/L).
Analysis 8.11
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.11
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 11 HDL‐cholesterol (mmol/L).
Analysis 8.12
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.12
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 12 LDL‐cholesterol (mmol/L).
Analysis 9.1
Comparison 9 Liraglutide 1.2 mg…
Analysis 9.1
Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 1 HbA1c.
Analysis 9.2
Comparison 9 Liraglutide 1.2 mg…
Analysis 9.2
Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 2 Patients reaching HbA1c…
Analysis 9.3
Comparison 9 Liraglutide 1.2 mg…
Analysis 9.3
Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 3 Weight.
Analysis 9.4
Comparison 9 Liraglutide 1.2 mg…
Analysis 9.4
Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 4 Systolic blood pressure.
Analysis 10.1
Comparison 10 Liraglutide versus insulin…
Analysis 10.1
Comparison 10 Liraglutide versus insulin glargine, Outcome 1 HbA1c.
Analysis 10.2
Comparison 10 Liraglutide versus insulin…
Analysis 10.2
Comparison 10 Liraglutide versus insulin glargine, Outcome 2 HbA1c
Analysis 10.3
Comparison 10 Liraglutide versus insulin…
Analysis 10.3
Comparison 10 Liraglutide versus insulin glargine, Outcome 3 Hypoglycaemia.
Analysis 10.4
Comparison 10 Liraglutide versus insulin…
Analysis 10.4
Comparison 10 Liraglutide versus insulin glargine, Outcome 4 Weight change.
Analysis 10.6
Comparison 10 Liraglutide versus insulin…
Analysis 10.6
Comparison 10 Liraglutide versus insulin glargine, Outcome 6 Systolic blood pressure.
Analysis 10.7
Comparison 10 Liraglutide versus insulin…
Analysis 10.7
Comparison 10 Liraglutide versus insulin glargine, Outcome 7 Fasting plasma glucose (mmol/L).
Analysis 11.1
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.1
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 1 HbA1c (%).
Analysis 11.2
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.2
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 2 HbA1c
Analysis 11.3
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.3
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia (mild/moderate/overall).
Analysis 11.5
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.5
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 5 Weight change.
Analysis 11.9
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.9
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma glucose…
Analysis 12.1
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.1
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 1 HbA1c (%).
Analysis 12.2
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.2
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 2 HbA1c
Analysis 12.3
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.3
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia.
Analysis 12.5
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.5
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 5 Weight change (kg).
Analysis 12.9
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.9
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma glucose…
Analysis 13.1
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.1
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 1 HbA1c (%).
Analysis 13.2
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.2
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 2 HbA1c
Analysis 13.3
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.3
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia (mild/moderate/overall).
Analysis 13.5
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.5
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change…
Analysis 13.7
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.7
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood…
Analysis 13.9
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.9
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma…
Analysis 14.1
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.1
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 1 HbA1c (%).
Analysis 14.2
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.2
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 2 HbA1c
Analysis 14.3
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.3
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia.
Analysis 14.5
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.5
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change…
Analysis 14.7
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.7
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood…
Analysis 14.9
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.9
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma…
Analysis 15.2
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.2
Comparison 15 Lixisenatide versus placebo, Outcome 2 HbA1c
Analysis 15.3
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.3
Comparison 15 Lixisenatide versus placebo, Outcome 3 Symptomatic hypoglycaemia.
Analysis 15.4
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.4
Comparison 15 Lixisenatide versus placebo, Outcome 4 Weight change (kg).
Analysis 15.6
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.6
Comparison 15 Lixisenatide versus placebo, Outcome 6 Fasting plasma glucose (mmol/L).
Analysis 15.7
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.7
Comparison 15 Lixisenatide versus placebo, Outcome 7 Post‐prandial glucose (mmol/L).
Analysis 15.8
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.8
Comparison 15 Lixisenatide versus placebo, Outcome 8 Average self‐monitored 7‐point blood glucose (mmol/L).
Analysis 16.1
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.1
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 1 HbA1c.
Analysis 16.3
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.3
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 3 HbA1c
Analysis 16.4
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.4
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 4 Hypoglycaemia.
Analysis 16.5
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.5
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 5 Weight change.
Analysis 16.8
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.8
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 8 Systolic blood pressure.
Analysis 16.10
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.10
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 17.1
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.1
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 1 HbA1c (%).
Analysis 17.3
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.3
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 3 HbA1c
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 4 Hypoglycaemia.
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 5 Weight change (kg).
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 8 Systolic blood pressure…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 10 Fasting plasma glucose…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo, Outcome 1 HbA1c (%).
Analysis 18.3
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.3
Comparison 18 Taspoglutide versus placebo, Outcome 3 HbA1c
Analysis 18.5
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.5
Comparison 18 Taspoglutide versus placebo, Outcome 5 Hypoglycaemia.
Analysis 18.7
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.7
Comparison 18 Taspoglutide versus placebo, Outcome 7 Weight change (kg).
Analysis 18.11
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.11
Comparison 18 Taspoglutide versus placebo, Outcome 11 Fasting plasma glucose (mmol/L).
Analysis 19.4
Comparison 19 LY2189265 versus placebo,…
Analysis 19.4
Comparison 19 LY2189265 versus placebo, Outcome 4 Weight change (kg).
Analysis 19.6
Comparison 19 LY2189265 versus placebo,…
Analysis 19.6
Comparison 19 LY2189265 versus placebo, Outcome 6 Systolic blood pressure (mm Hg).
Analysis 19.7
Comparison 19 LY2189265 versus placebo,…
Analysis 19.7
Comparison 19 LY2189265 versus placebo, Outcome 7 Diastolic blood pressure (mm Hg).
Analysis 20.1
Comparison 20 GLP‐1 agonist versus…
Analysis 20.1
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 1 HbA1c.
Analysis 20.2
Comparison 20 GLP‐1 agonist versus…
Analysis 20.2
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 2 HbA1c
Analysis 20.3
Comparison 20 GLP‐1 agonist versus…
Analysis 20.3
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 3 Hypoglycaemia.
Analysis 20.5
Comparison 20 GLP‐1 agonist versus…
Analysis 20.5
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 5 Weight change.
Analysis 20.9
Comparison 20 GLP‐1 agonist versus…
Analysis 20.9
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 9 Systolic blood pressure.
Analysis 20.10
Comparison 20 GLP‐1 agonist versus…
Analysis 20.10
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 20.12
Comparison 20 GLP‐1 agonist versus…
Analysis 20.12
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 12 Triglycerides (mmol/L).
Analysis 20.13
Comparison 20 GLP‐1 agonist versus…
Analysis 20.13
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 13 Total cholesterol (mmol/L).
Analysis 20.14
Comparison 20 GLP‐1 agonist versus…
Analysis 20.14
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 14 HDL‐cholesterol (mmol/L).
Analysis 20.15
Comparison 20 GLP‐1 agonist versus…
Analysis 20.15
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 15 LDL‐cholesterol (mmol/L).
- [Efficacy of GLP-1-analogs in type 2 diabetes mellitus].Schütt M. Schütt M. Dtsch Med Wochenschr. 2013 Jan;138(1-2):15. doi: 10.1055/s-0032-1329135. Epub 2012 Dec 18. Dtsch Med Wochenschr. 2013. PMID: 23250688 German. No abstract available.
- Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Hemmingsen B, et al. Cochrane Database Syst Rev. 2017 May 10;5(5):CD012204. doi: 10.1002/14651858.CD012204.pub2. Cochrane Database Syst Rev. 2017. PMID: 28489279 Free PMC article. Review.
- Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis.Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR. Shyangdan DS, et al. BMC Endocr Disord. 2010 Dec 9;10:20. doi: 10.1186/1472-6823-10-20. BMC Endocr Disord. 2010. PMID: 21143938 Free PMC article.
- Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S. Waugh N, et al. Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Health Technol Assess. 2010. PMID: 20646668 Review.
- Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Htike ZZ, et al. Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17. Diabetes Obes Metab. 2017. PMID: 27981757 Review.
- Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.Pinelli NR, Hurren KM. Pinelli NR, et al. Ann Pharmacother. 2011 Jul;45(7-8):850-60. doi: 10.1345/aph.1Q024. Epub 2011 Jul 5. Ann Pharmacother. 2011. PMID: 21730278 Review.
- Effects of synbiotics supplementation on anthropometric and lipid profile parameters: Finding from an umbrella meta-analysis.Musazadeh V, Mohammadi Anilou M, Vajdi M, Karimi A, Sedgh Ahrabi S, Dehghan P. Musazadeh V, et al. Front Nutr. 2023 Feb 23;10:1121541. doi: 10.3389/fnut.2023.1121541. eCollection 2023. Front Nutr. 2023. PMID: 36908920 Free PMC article.
- Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients.Silva-Nunes J, Nascimento E, Louro J, Dores J, Laginha T, Gonçalves-Ferreira A, Alves M, Souto SB, Cunha N, Pina E, Duarte R, Raposo JF. Silva-Nunes J, et al. Metabolites. 2022 Nov 16;12(11):1121. doi: 10.3390/metabo12111121. Metabolites. 2022. PMID: 36422260 Free PMC article.
- Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data.Zhao Z, Tang Y, Hu Y, Zhu H, Chen X, Zhao B. Zhao Z, et al. Ann Transl Med. 2021 Sep;9(18):1482. doi: 10.21037/atm-21-4162. Ann Transl Med. 2021. PMID: 34734034 Free PMC article.
- Anti-Obesity Effect of Polygalin C Isolated from Polygala japonica Houtt. via Suppression of the Adipogenic and Lipogenic Factors in 3T3-L1 Adipocytes.Jee W, Lee SH, Ko HM, Jung JH, Chung WS, Jang HJ. Jee W, et al. Int J Mol Sci. 2021 Sep 27;22(19):10405. doi: 10.3390/ijms221910405. Int J Mol Sci. 2021. PMID: 34638751 Free PMC article.
- Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.Wong C, Lee MH, Yaow CYL, Chin YH, Goh XL, Ng CH, Lim AYL, Muthiah MD, Khoo CM. Wong C, et al. Front Endocrinol (Lausanne). 2021 Apr 9;12:609110. doi: 10.3389/fendo.2021.609110. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33897616 Free PMC article.
- Meta-Analysis
- Review
- Systematic Review
- Diabetes Mellitus, Type 2 / blood
- Diabetes Mellitus, Type 2 / drug therapy*
- Glucagon-Like Peptide 1 / analogs & derivatives*
- Glycated Hemoglobin / metabolism
- Humans
- Hypoglycemic Agents / therapeutic use*
- Randomized Controlled Trials as Topic
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Glucagon-Like Peptide 1
- Full Text Sources
- Medical
NCBI Literature Resources
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
![Analysis 7.3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-007-03.jpg)
![Analysis 7.4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-007-04.jpg)
![Analysis 7.6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-007-06.jpg)
![Analysis 7.7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-007-07.jpg)
![Analysis 7.9](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-007-09.jpg)
![Analysis 7.10](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-007-10.jpg)
![Analysis 7.11](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-007-11.jpg)
![Analysis 7.12](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-007-12.jpg)
![Analysis 8.1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-008-01.jpg)
![Analysis 8.2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-008-02.jpg)
Analysis 8.3
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.3
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 3 Hypoglycaemia.
Analysis 8.4
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.4
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 4 Weight change.
Analysis 8.6
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.6
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 6 Systolic blood pressure.
Analysis 8.7
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.7
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 7 Fasting plasma glucose (mmol/L).
Analysis 8.9
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.9
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 9 Triglycerides (mmol/L).
Analysis 8.10
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.10
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 10 Total cholesterol (mmol/L).
Analysis 8.11
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.11
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 11 HDL‐cholesterol (mmol/L).
Analysis 8.12
Comparison 8 Liraglutide 1.8 mg…
Analysis 8.12
Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 12 LDL‐cholesterol (mmol/L).
Analysis 9.1
Comparison 9 Liraglutide 1.2 mg…
Analysis 9.1
Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 1 HbA1c.
Analysis 9.2
Comparison 9 Liraglutide 1.2 mg…
Analysis 9.2
Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 2 Patients reaching HbA1c…
Analysis 9.3
Comparison 9 Liraglutide 1.2 mg…
Analysis 9.3
Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 3 Weight.
Analysis 9.4
Comparison 9 Liraglutide 1.2 mg…
Analysis 9.4
Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 4 Systolic blood pressure.
Analysis 10.1
Comparison 10 Liraglutide versus insulin…
Analysis 10.1
Comparison 10 Liraglutide versus insulin glargine, Outcome 1 HbA1c.
Analysis 10.2
Comparison 10 Liraglutide versus insulin…
Analysis 10.2
Comparison 10 Liraglutide versus insulin glargine, Outcome 2 HbA1c
Analysis 10.3
Comparison 10 Liraglutide versus insulin…
Analysis 10.3
Comparison 10 Liraglutide versus insulin glargine, Outcome 3 Hypoglycaemia.
Analysis 10.4
Comparison 10 Liraglutide versus insulin…
Analysis 10.4
Comparison 10 Liraglutide versus insulin glargine, Outcome 4 Weight change.
Analysis 10.6
Comparison 10 Liraglutide versus insulin…
Analysis 10.6
Comparison 10 Liraglutide versus insulin glargine, Outcome 6 Systolic blood pressure.
Analysis 10.7
Comparison 10 Liraglutide versus insulin…
Analysis 10.7
Comparison 10 Liraglutide versus insulin glargine, Outcome 7 Fasting plasma glucose (mmol/L).
Analysis 11.1
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.1
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 1 HbA1c (%).
Analysis 11.2
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.2
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 2 HbA1c
Analysis 11.3
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.3
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia (mild/moderate/overall).
Analysis 11.5
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.5
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 5 Weight change.
Analysis 11.9
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.9
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma glucose…
Analysis 12.1
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.1
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 1 HbA1c (%).
Analysis 12.2
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.2
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 2 HbA1c
Analysis 12.3
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.3
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia.
Analysis 12.5
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.5
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 5 Weight change (kg).
Analysis 12.9
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.9
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma glucose…
Analysis 13.1
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.1
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 1 HbA1c (%).
Analysis 13.2
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.2
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 2 HbA1c
Analysis 13.3
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.3
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia (mild/moderate/overall).
Analysis 13.5
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.5
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change…
Analysis 13.7
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.7
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood…
Analysis 13.9
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.9
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma…
Analysis 14.1
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.1
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 1 HbA1c (%).
Analysis 14.2
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.2
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 2 HbA1c
Analysis 14.3
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.3
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia.
Analysis 14.5
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.5
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change…
Analysis 14.7
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.7
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood…
Analysis 14.9
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.9
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma…
Analysis 15.2
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.2
Comparison 15 Lixisenatide versus placebo, Outcome 2 HbA1c
Analysis 15.3
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.3
Comparison 15 Lixisenatide versus placebo, Outcome 3 Symptomatic hypoglycaemia.
Analysis 15.4
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.4
Comparison 15 Lixisenatide versus placebo, Outcome 4 Weight change (kg).
Analysis 15.6
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.6
Comparison 15 Lixisenatide versus placebo, Outcome 6 Fasting plasma glucose (mmol/L).
Analysis 15.7
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.7
Comparison 15 Lixisenatide versus placebo, Outcome 7 Post‐prandial glucose (mmol/L).
Analysis 15.8
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.8
Comparison 15 Lixisenatide versus placebo, Outcome 8 Average self‐monitored 7‐point blood glucose (mmol/L).
Analysis 16.1
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.1
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 1 HbA1c.
Analysis 16.3
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.3
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 3 HbA1c
Analysis 16.4
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.4
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 4 Hypoglycaemia.
Analysis 16.5
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.5
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 5 Weight change.
Analysis 16.8
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.8
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 8 Systolic blood pressure.
Analysis 16.10
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.10
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 17.1
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.1
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 1 HbA1c (%).
Analysis 17.3
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.3
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 3 HbA1c
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 4 Hypoglycaemia.
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 5 Weight change (kg).
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 8 Systolic blood pressure…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 10 Fasting plasma glucose…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo, Outcome 1 HbA1c (%).
Analysis 18.3
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.3
Comparison 18 Taspoglutide versus placebo, Outcome 3 HbA1c
Analysis 18.5
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.5
Comparison 18 Taspoglutide versus placebo, Outcome 5 Hypoglycaemia.
Analysis 18.7
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.7
Comparison 18 Taspoglutide versus placebo, Outcome 7 Weight change (kg).
Analysis 18.11
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.11
Comparison 18 Taspoglutide versus placebo, Outcome 11 Fasting plasma glucose (mmol/L).
Analysis 19.4
Comparison 19 LY2189265 versus placebo,…
Analysis 19.4
Comparison 19 LY2189265 versus placebo, Outcome 4 Weight change (kg).
Analysis 19.6
Comparison 19 LY2189265 versus placebo,…
Analysis 19.6
Comparison 19 LY2189265 versus placebo, Outcome 6 Systolic blood pressure (mm Hg).
Analysis 19.7
Comparison 19 LY2189265 versus placebo,…
Analysis 19.7
Comparison 19 LY2189265 versus placebo, Outcome 7 Diastolic blood pressure (mm Hg).
Analysis 20.1
Comparison 20 GLP‐1 agonist versus…
Analysis 20.1
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 1 HbA1c.
Analysis 20.2
Comparison 20 GLP‐1 agonist versus…
Analysis 20.2
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 2 HbA1c
Analysis 20.3
Comparison 20 GLP‐1 agonist versus…
Analysis 20.3
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 3 Hypoglycaemia.
Analysis 20.5
Comparison 20 GLP‐1 agonist versus…
Analysis 20.5
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 5 Weight change.
Analysis 20.9
Comparison 20 GLP‐1 agonist versus…
Analysis 20.9
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 9 Systolic blood pressure.
Analysis 20.10
Comparison 20 GLP‐1 agonist versus…
Analysis 20.10
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 20.12
Comparison 20 GLP‐1 agonist versus…
Analysis 20.12
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 12 Triglycerides (mmol/L).
Analysis 20.13
Comparison 20 GLP‐1 agonist versus…
Analysis 20.13
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 13 Total cholesterol (mmol/L).
Analysis 20.14
Comparison 20 GLP‐1 agonist versus…
Analysis 20.14
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 14 HDL‐cholesterol (mmol/L).
Analysis 20.15
Comparison 20 GLP‐1 agonist versus…
Analysis 20.15
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 15 LDL‐cholesterol (mmol/L).
- [Efficacy of GLP-1-analogs in type 2 diabetes mellitus].Schütt M. Schütt M. Dtsch Med Wochenschr. 2013 Jan;138(1-2):15. doi: 10.1055/s-0032-1329135. Epub 2012 Dec 18. Dtsch Med Wochenschr. 2013. PMID: 23250688 German. No abstract available.
- Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Hemmingsen B, et al. Cochrane Database Syst Rev. 2017 May 10;5(5):CD012204. doi: 10.1002/14651858.CD012204.pub2. Cochrane Database Syst Rev. 2017. PMID: 28489279 Free PMC article. Review.
- Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis.Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR. Shyangdan DS, et al. BMC Endocr Disord. 2010 Dec 9;10:20. doi: 10.1186/1472-6823-10-20. BMC Endocr Disord. 2010. PMID: 21143938 Free PMC article.
- Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S. Waugh N, et al. Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Health Technol Assess. 2010. PMID: 20646668 Review.
- Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Htike ZZ, et al. Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17. Diabetes Obes Metab. 2017. PMID: 27981757 Review.
- Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.Pinelli NR, Hurren KM. Pinelli NR, et al. Ann Pharmacother. 2011 Jul;45(7-8):850-60. doi: 10.1345/aph.1Q024. Epub 2011 Jul 5. Ann Pharmacother. 2011. PMID: 21730278 Review.
- Effects of synbiotics supplementation on anthropometric and lipid profile parameters: Finding from an umbrella meta-analysis.Musazadeh V, Mohammadi Anilou M, Vajdi M, Karimi A, Sedgh Ahrabi S, Dehghan P. Musazadeh V, et al. Front Nutr. 2023 Feb 23;10:1121541. doi: 10.3389/fnut.2023.1121541. eCollection 2023. Front Nutr. 2023. PMID: 36908920 Free PMC article.
- Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients.Silva-Nunes J, Nascimento E, Louro J, Dores J, Laginha T, Gonçalves-Ferreira A, Alves M, Souto SB, Cunha N, Pina E, Duarte R, Raposo JF. Silva-Nunes J, et al. Metabolites. 2022 Nov 16;12(11):1121. doi: 10.3390/metabo12111121. Metabolites. 2022. PMID: 36422260 Free PMC article.
- Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data.Zhao Z, Tang Y, Hu Y, Zhu H, Chen X, Zhao B. Zhao Z, et al. Ann Transl Med. 2021 Sep;9(18):1482. doi: 10.21037/atm-21-4162. Ann Transl Med. 2021. PMID: 34734034 Free PMC article.
- Anti-Obesity Effect of Polygalin C Isolated from Polygala japonica Houtt. via Suppression of the Adipogenic and Lipogenic Factors in 3T3-L1 Adipocytes.Jee W, Lee SH, Ko HM, Jung JH, Chung WS, Jang HJ. Jee W, et al. Int J Mol Sci. 2021 Sep 27;22(19):10405. doi: 10.3390/ijms221910405. Int J Mol Sci. 2021. PMID: 34638751 Free PMC article.
- Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.Wong C, Lee MH, Yaow CYL, Chin YH, Goh XL, Ng CH, Lim AYL, Muthiah MD, Khoo CM. Wong C, et al. Front Endocrinol (Lausanne). 2021 Apr 9;12:609110. doi: 10.3389/fendo.2021.609110. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33897616 Free PMC article.
- Meta-Analysis
- Review
- Systematic Review
- Diabetes Mellitus, Type 2 / blood
- Diabetes Mellitus, Type 2 / drug therapy*
- Glucagon-Like Peptide 1 / analogs & derivatives*
- Glycated Hemoglobin / metabolism
- Humans
- Hypoglycemic Agents / therapeutic use*
- Randomized Controlled Trials as Topic
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Glucagon-Like Peptide 1
- Full Text Sources
- Medical
NCBI Literature Resources
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
![Analysis 8.3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-008-03.jpg)
![Analysis 8.4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-008-04.jpg)
![Analysis 8.6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-008-06.jpg)
![Analysis 8.7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-008-07.jpg)
![Analysis 8.9](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-008-09.jpg)
![Analysis 8.10](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-008-10.jpg)
![Analysis 8.11](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-008-11.jpg)
![Analysis 8.12](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-008-12.jpg)
![Analysis 9.1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-009-01.jpg)
![Analysis 9.2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-009-02.jpg)
Analysis 9.3
Comparison 9 Liraglutide 1.2 mg…
Analysis 9.3
Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 3 Weight.
Analysis 9.4
Comparison 9 Liraglutide 1.2 mg…
Analysis 9.4
Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 4 Systolic blood pressure.
Analysis 10.1
Comparison 10 Liraglutide versus insulin…
Analysis 10.1
Comparison 10 Liraglutide versus insulin glargine, Outcome 1 HbA1c.
Analysis 10.2
Comparison 10 Liraglutide versus insulin…
Analysis 10.2
Comparison 10 Liraglutide versus insulin glargine, Outcome 2 HbA1c
Analysis 10.3
Comparison 10 Liraglutide versus insulin…
Analysis 10.3
Comparison 10 Liraglutide versus insulin glargine, Outcome 3 Hypoglycaemia.
Analysis 10.4
Comparison 10 Liraglutide versus insulin…
Analysis 10.4
Comparison 10 Liraglutide versus insulin glargine, Outcome 4 Weight change.
Analysis 10.6
Comparison 10 Liraglutide versus insulin…
Analysis 10.6
Comparison 10 Liraglutide versus insulin glargine, Outcome 6 Systolic blood pressure.
Analysis 10.7
Comparison 10 Liraglutide versus insulin…
Analysis 10.7
Comparison 10 Liraglutide versus insulin glargine, Outcome 7 Fasting plasma glucose (mmol/L).
Analysis 11.1
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.1
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 1 HbA1c (%).
Analysis 11.2
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.2
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 2 HbA1c
Analysis 11.3
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.3
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia (mild/moderate/overall).
Analysis 11.5
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.5
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 5 Weight change.
Analysis 11.9
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.9
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma glucose…
Analysis 12.1
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.1
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 1 HbA1c (%).
Analysis 12.2
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.2
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 2 HbA1c
Analysis 12.3
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.3
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia.
Analysis 12.5
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.5
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 5 Weight change (kg).
Analysis 12.9
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.9
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma glucose…
Analysis 13.1
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.1
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 1 HbA1c (%).
Analysis 13.2
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.2
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 2 HbA1c
Analysis 13.3
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.3
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia (mild/moderate/overall).
Analysis 13.5
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.5
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change…
Analysis 13.7
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.7
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood…
Analysis 13.9
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.9
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma…
Analysis 14.1
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.1
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 1 HbA1c (%).
Analysis 14.2
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.2
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 2 HbA1c
Analysis 14.3
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.3
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia.
Analysis 14.5
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.5
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change…
Analysis 14.7
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.7
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood…
Analysis 14.9
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.9
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma…
Analysis 15.2
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.2
Comparison 15 Lixisenatide versus placebo, Outcome 2 HbA1c
Analysis 15.3
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.3
Comparison 15 Lixisenatide versus placebo, Outcome 3 Symptomatic hypoglycaemia.
Analysis 15.4
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.4
Comparison 15 Lixisenatide versus placebo, Outcome 4 Weight change (kg).
Analysis 15.6
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.6
Comparison 15 Lixisenatide versus placebo, Outcome 6 Fasting plasma glucose (mmol/L).
Analysis 15.7
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.7
Comparison 15 Lixisenatide versus placebo, Outcome 7 Post‐prandial glucose (mmol/L).
Analysis 15.8
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.8
Comparison 15 Lixisenatide versus placebo, Outcome 8 Average self‐monitored 7‐point blood glucose (mmol/L).
Analysis 16.1
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.1
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 1 HbA1c.
Analysis 16.3
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.3
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 3 HbA1c
Analysis 16.4
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.4
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 4 Hypoglycaemia.
Analysis 16.5
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.5
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 5 Weight change.
Analysis 16.8
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.8
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 8 Systolic blood pressure.
Analysis 16.10
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.10
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 17.1
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.1
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 1 HbA1c (%).
Analysis 17.3
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.3
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 3 HbA1c
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 4 Hypoglycaemia.
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 5 Weight change (kg).
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 8 Systolic blood pressure…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 10 Fasting plasma glucose…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo, Outcome 1 HbA1c (%).
Analysis 18.3
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.3
Comparison 18 Taspoglutide versus placebo, Outcome 3 HbA1c
Analysis 18.5
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.5
Comparison 18 Taspoglutide versus placebo, Outcome 5 Hypoglycaemia.
Analysis 18.7
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.7
Comparison 18 Taspoglutide versus placebo, Outcome 7 Weight change (kg).
Analysis 18.11
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.11
Comparison 18 Taspoglutide versus placebo, Outcome 11 Fasting plasma glucose (mmol/L).
Analysis 19.4
Comparison 19 LY2189265 versus placebo,…
Analysis 19.4
Comparison 19 LY2189265 versus placebo, Outcome 4 Weight change (kg).
Analysis 19.6
Comparison 19 LY2189265 versus placebo,…
Analysis 19.6
Comparison 19 LY2189265 versus placebo, Outcome 6 Systolic blood pressure (mm Hg).
Analysis 19.7
Comparison 19 LY2189265 versus placebo,…
Analysis 19.7
Comparison 19 LY2189265 versus placebo, Outcome 7 Diastolic blood pressure (mm Hg).
Analysis 20.1
Comparison 20 GLP‐1 agonist versus…
Analysis 20.1
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 1 HbA1c.
Analysis 20.2
Comparison 20 GLP‐1 agonist versus…
Analysis 20.2
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 2 HbA1c
Analysis 20.3
Comparison 20 GLP‐1 agonist versus…
Analysis 20.3
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 3 Hypoglycaemia.
Analysis 20.5
Comparison 20 GLP‐1 agonist versus…
Analysis 20.5
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 5 Weight change.
Analysis 20.9
Comparison 20 GLP‐1 agonist versus…
Analysis 20.9
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 9 Systolic blood pressure.
Analysis 20.10
Comparison 20 GLP‐1 agonist versus…
Analysis 20.10
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 20.12
Comparison 20 GLP‐1 agonist versus…
Analysis 20.12
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 12 Triglycerides (mmol/L).
Analysis 20.13
Comparison 20 GLP‐1 agonist versus…
Analysis 20.13
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 13 Total cholesterol (mmol/L).
Analysis 20.14
Comparison 20 GLP‐1 agonist versus…
Analysis 20.14
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 14 HDL‐cholesterol (mmol/L).
Analysis 20.15
Comparison 20 GLP‐1 agonist versus…
Analysis 20.15
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 15 LDL‐cholesterol (mmol/L).
- [Efficacy of GLP-1-analogs in type 2 diabetes mellitus].Schütt M. Schütt M. Dtsch Med Wochenschr. 2013 Jan;138(1-2):15. doi: 10.1055/s-0032-1329135. Epub 2012 Dec 18. Dtsch Med Wochenschr. 2013. PMID: 23250688 German. No abstract available.
- Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Hemmingsen B, et al. Cochrane Database Syst Rev. 2017 May 10;5(5):CD012204. doi: 10.1002/14651858.CD012204.pub2. Cochrane Database Syst Rev. 2017. PMID: 28489279 Free PMC article. Review.
- Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis.Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR. Shyangdan DS, et al. BMC Endocr Disord. 2010 Dec 9;10:20. doi: 10.1186/1472-6823-10-20. BMC Endocr Disord. 2010. PMID: 21143938 Free PMC article.
- Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S. Waugh N, et al. Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Health Technol Assess. 2010. PMID: 20646668 Review.
- Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Htike ZZ, et al. Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17. Diabetes Obes Metab. 2017. PMID: 27981757 Review.
- Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.Pinelli NR, Hurren KM. Pinelli NR, et al. Ann Pharmacother. 2011 Jul;45(7-8):850-60. doi: 10.1345/aph.1Q024. Epub 2011 Jul 5. Ann Pharmacother. 2011. PMID: 21730278 Review.
- Effects of synbiotics supplementation on anthropometric and lipid profile parameters: Finding from an umbrella meta-analysis.Musazadeh V, Mohammadi Anilou M, Vajdi M, Karimi A, Sedgh Ahrabi S, Dehghan P. Musazadeh V, et al. Front Nutr. 2023 Feb 23;10:1121541. doi: 10.3389/fnut.2023.1121541. eCollection 2023. Front Nutr. 2023. PMID: 36908920 Free PMC article.
- Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients.Silva-Nunes J, Nascimento E, Louro J, Dores J, Laginha T, Gonçalves-Ferreira A, Alves M, Souto SB, Cunha N, Pina E, Duarte R, Raposo JF. Silva-Nunes J, et al. Metabolites. 2022 Nov 16;12(11):1121. doi: 10.3390/metabo12111121. Metabolites. 2022. PMID: 36422260 Free PMC article.
- Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data.Zhao Z, Tang Y, Hu Y, Zhu H, Chen X, Zhao B. Zhao Z, et al. Ann Transl Med. 2021 Sep;9(18):1482. doi: 10.21037/atm-21-4162. Ann Transl Med. 2021. PMID: 34734034 Free PMC article.
- Anti-Obesity Effect of Polygalin C Isolated from Polygala japonica Houtt. via Suppression of the Adipogenic and Lipogenic Factors in 3T3-L1 Adipocytes.Jee W, Lee SH, Ko HM, Jung JH, Chung WS, Jang HJ. Jee W, et al. Int J Mol Sci. 2021 Sep 27;22(19):10405. doi: 10.3390/ijms221910405. Int J Mol Sci. 2021. PMID: 34638751 Free PMC article.
- Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.Wong C, Lee MH, Yaow CYL, Chin YH, Goh XL, Ng CH, Lim AYL, Muthiah MD, Khoo CM. Wong C, et al. Front Endocrinol (Lausanne). 2021 Apr 9;12:609110. doi: 10.3389/fendo.2021.609110. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33897616 Free PMC article.
- Meta-Analysis
- Review
- Systematic Review
- Diabetes Mellitus, Type 2 / blood
- Diabetes Mellitus, Type 2 / drug therapy*
- Glucagon-Like Peptide 1 / analogs & derivatives*
- Glycated Hemoglobin / metabolism
- Humans
- Hypoglycemic Agents / therapeutic use*
- Randomized Controlled Trials as Topic
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Glucagon-Like Peptide 1
- Full Text Sources
- Medical
NCBI Literature Resources
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
![Analysis 9.3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-009-03.jpg)
![Analysis 9.4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-009-04.jpg)
![Analysis 10.1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-010-01.jpg)
![Analysis 10.2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-010-02.jpg)
Analysis 10.3
Comparison 10 Liraglutide versus insulin…
Analysis 10.3
Comparison 10 Liraglutide versus insulin glargine, Outcome 3 Hypoglycaemia.
Analysis 10.4
Comparison 10 Liraglutide versus insulin…
Analysis 10.4
Comparison 10 Liraglutide versus insulin glargine, Outcome 4 Weight change.
Analysis 10.6
Comparison 10 Liraglutide versus insulin…
Analysis 10.6
Comparison 10 Liraglutide versus insulin glargine, Outcome 6 Systolic blood pressure.
Analysis 10.7
Comparison 10 Liraglutide versus insulin…
Analysis 10.7
Comparison 10 Liraglutide versus insulin glargine, Outcome 7 Fasting plasma glucose (mmol/L).
Analysis 11.1
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.1
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 1 HbA1c (%).
Analysis 11.2
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.2
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 2 HbA1c
Analysis 11.3
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.3
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia (mild/moderate/overall).
Analysis 11.5
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.5
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 5 Weight change.
Analysis 11.9
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.9
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma glucose…
Analysis 12.1
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.1
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 1 HbA1c (%).
Analysis 12.2
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.2
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 2 HbA1c
Analysis 12.3
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.3
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia.
Analysis 12.5
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.5
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 5 Weight change (kg).
Analysis 12.9
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.9
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma glucose…
Analysis 13.1
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.1
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 1 HbA1c (%).
Analysis 13.2
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.2
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 2 HbA1c
Analysis 13.3
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.3
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia (mild/moderate/overall).
Analysis 13.5
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.5
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change…
Analysis 13.7
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.7
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood…
Analysis 13.9
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.9
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma…
Analysis 14.1
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.1
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 1 HbA1c (%).
Analysis 14.2
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.2
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 2 HbA1c
Analysis 14.3
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.3
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia.
Analysis 14.5
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.5
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change…
Analysis 14.7
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.7
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood…
Analysis 14.9
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.9
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma…
Analysis 15.2
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.2
Comparison 15 Lixisenatide versus placebo, Outcome 2 HbA1c
Analysis 15.3
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.3
Comparison 15 Lixisenatide versus placebo, Outcome 3 Symptomatic hypoglycaemia.
Analysis 15.4
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.4
Comparison 15 Lixisenatide versus placebo, Outcome 4 Weight change (kg).
Analysis 15.6
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.6
Comparison 15 Lixisenatide versus placebo, Outcome 6 Fasting plasma glucose (mmol/L).
Analysis 15.7
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.7
Comparison 15 Lixisenatide versus placebo, Outcome 7 Post‐prandial glucose (mmol/L).
Analysis 15.8
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.8
Comparison 15 Lixisenatide versus placebo, Outcome 8 Average self‐monitored 7‐point blood glucose (mmol/L).
Analysis 16.1
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.1
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 1 HbA1c.
Analysis 16.3
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.3
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 3 HbA1c
Analysis 16.4
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.4
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 4 Hypoglycaemia.
Analysis 16.5
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.5
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 5 Weight change.
Analysis 16.8
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.8
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 8 Systolic blood pressure.
Analysis 16.10
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.10
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 17.1
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.1
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 1 HbA1c (%).
Analysis 17.3
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.3
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 3 HbA1c
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 4 Hypoglycaemia.
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 5 Weight change (kg).
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 8 Systolic blood pressure…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 10 Fasting plasma glucose…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo, Outcome 1 HbA1c (%).
Analysis 18.3
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.3
Comparison 18 Taspoglutide versus placebo, Outcome 3 HbA1c
Analysis 18.5
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.5
Comparison 18 Taspoglutide versus placebo, Outcome 5 Hypoglycaemia.
Analysis 18.7
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.7
Comparison 18 Taspoglutide versus placebo, Outcome 7 Weight change (kg).
Analysis 18.11
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.11
Comparison 18 Taspoglutide versus placebo, Outcome 11 Fasting plasma glucose (mmol/L).
Analysis 19.4
Comparison 19 LY2189265 versus placebo,…
Analysis 19.4
Comparison 19 LY2189265 versus placebo, Outcome 4 Weight change (kg).
Analysis 19.6
Comparison 19 LY2189265 versus placebo,…
Analysis 19.6
Comparison 19 LY2189265 versus placebo, Outcome 6 Systolic blood pressure (mm Hg).
Analysis 19.7
Comparison 19 LY2189265 versus placebo,…
Analysis 19.7
Comparison 19 LY2189265 versus placebo, Outcome 7 Diastolic blood pressure (mm Hg).
Analysis 20.1
Comparison 20 GLP‐1 agonist versus…
Analysis 20.1
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 1 HbA1c.
Analysis 20.2
Comparison 20 GLP‐1 agonist versus…
Analysis 20.2
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 2 HbA1c
Analysis 20.3
Comparison 20 GLP‐1 agonist versus…
Analysis 20.3
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 3 Hypoglycaemia.
Analysis 20.5
Comparison 20 GLP‐1 agonist versus…
Analysis 20.5
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 5 Weight change.
Analysis 20.9
Comparison 20 GLP‐1 agonist versus…
Analysis 20.9
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 9 Systolic blood pressure.
Analysis 20.10
Comparison 20 GLP‐1 agonist versus…
Analysis 20.10
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 20.12
Comparison 20 GLP‐1 agonist versus…
Analysis 20.12
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 12 Triglycerides (mmol/L).
Analysis 20.13
Comparison 20 GLP‐1 agonist versus…
Analysis 20.13
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 13 Total cholesterol (mmol/L).
Analysis 20.14
Comparison 20 GLP‐1 agonist versus…
Analysis 20.14
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 14 HDL‐cholesterol (mmol/L).
Analysis 20.15
Comparison 20 GLP‐1 agonist versus…
Analysis 20.15
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 15 LDL‐cholesterol (mmol/L).
- [Efficacy of GLP-1-analogs in type 2 diabetes mellitus].Schütt M. Schütt M. Dtsch Med Wochenschr. 2013 Jan;138(1-2):15. doi: 10.1055/s-0032-1329135. Epub 2012 Dec 18. Dtsch Med Wochenschr. 2013. PMID: 23250688 German. No abstract available.
- Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Hemmingsen B, et al. Cochrane Database Syst Rev. 2017 May 10;5(5):CD012204. doi: 10.1002/14651858.CD012204.pub2. Cochrane Database Syst Rev. 2017. PMID: 28489279 Free PMC article. Review.
- Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis.Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR. Shyangdan DS, et al. BMC Endocr Disord. 2010 Dec 9;10:20. doi: 10.1186/1472-6823-10-20. BMC Endocr Disord. 2010. PMID: 21143938 Free PMC article.
- Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S. Waugh N, et al. Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Health Technol Assess. 2010. PMID: 20646668 Review.
- Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Htike ZZ, et al. Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17. Diabetes Obes Metab. 2017. PMID: 27981757 Review.
- Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.Pinelli NR, Hurren KM. Pinelli NR, et al. Ann Pharmacother. 2011 Jul;45(7-8):850-60. doi: 10.1345/aph.1Q024. Epub 2011 Jul 5. Ann Pharmacother. 2011. PMID: 21730278 Review.
- Effects of synbiotics supplementation on anthropometric and lipid profile parameters: Finding from an umbrella meta-analysis.Musazadeh V, Mohammadi Anilou M, Vajdi M, Karimi A, Sedgh Ahrabi S, Dehghan P. Musazadeh V, et al. Front Nutr. 2023 Feb 23;10:1121541. doi: 10.3389/fnut.2023.1121541. eCollection 2023. Front Nutr. 2023. PMID: 36908920 Free PMC article.
- Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients.Silva-Nunes J, Nascimento E, Louro J, Dores J, Laginha T, Gonçalves-Ferreira A, Alves M, Souto SB, Cunha N, Pina E, Duarte R, Raposo JF. Silva-Nunes J, et al. Metabolites. 2022 Nov 16;12(11):1121. doi: 10.3390/metabo12111121. Metabolites. 2022. PMID: 36422260 Free PMC article.
- Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data.Zhao Z, Tang Y, Hu Y, Zhu H, Chen X, Zhao B. Zhao Z, et al. Ann Transl Med. 2021 Sep;9(18):1482. doi: 10.21037/atm-21-4162. Ann Transl Med. 2021. PMID: 34734034 Free PMC article.
- Anti-Obesity Effect of Polygalin C Isolated from Polygala japonica Houtt. via Suppression of the Adipogenic and Lipogenic Factors in 3T3-L1 Adipocytes.Jee W, Lee SH, Ko HM, Jung JH, Chung WS, Jang HJ. Jee W, et al. Int J Mol Sci. 2021 Sep 27;22(19):10405. doi: 10.3390/ijms221910405. Int J Mol Sci. 2021. PMID: 34638751 Free PMC article.
- Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.Wong C, Lee MH, Yaow CYL, Chin YH, Goh XL, Ng CH, Lim AYL, Muthiah MD, Khoo CM. Wong C, et al. Front Endocrinol (Lausanne). 2021 Apr 9;12:609110. doi: 10.3389/fendo.2021.609110. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33897616 Free PMC article.
- Meta-Analysis
- Review
- Systematic Review
- Diabetes Mellitus, Type 2 / blood
- Diabetes Mellitus, Type 2 / drug therapy*
- Glucagon-Like Peptide 1 / analogs & derivatives*
- Glycated Hemoglobin / metabolism
- Humans
- Hypoglycemic Agents / therapeutic use*
- Randomized Controlled Trials as Topic
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Glucagon-Like Peptide 1
- Full Text Sources
- Medical
NCBI Literature Resources
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
![Analysis 10.3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-010-03.jpg)
![Analysis 10.4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-010-04.jpg)
![Analysis 10.6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-010-06.jpg)
![Analysis 10.7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-010-07.jpg)
![Analysis 11.1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-011-01.jpg)
![Analysis 11.2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-011-02.jpg)
Analysis 11.3
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.3
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia (mild/moderate/overall).
Analysis 11.5
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.5
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 5 Weight change.
Analysis 11.9
Comparison 11 Liraglutide 1.2 mg…
Analysis 11.9
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma glucose…
Analysis 12.1
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.1
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 1 HbA1c (%).
Analysis 12.2
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.2
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 2 HbA1c
Analysis 12.3
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.3
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia.
Analysis 12.5
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.5
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 5 Weight change (kg).
Analysis 12.9
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.9
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma glucose…
Analysis 13.1
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.1
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 1 HbA1c (%).
Analysis 13.2
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.2
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 2 HbA1c
Analysis 13.3
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.3
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia (mild/moderate/overall).
Analysis 13.5
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.5
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change…
Analysis 13.7
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.7
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood…
Analysis 13.9
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.9
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma…
Analysis 14.1
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.1
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 1 HbA1c (%).
Analysis 14.2
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.2
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 2 HbA1c
Analysis 14.3
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.3
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia.
Analysis 14.5
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.5
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change…
Analysis 14.7
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.7
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood…
Analysis 14.9
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.9
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma…
Analysis 15.2
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.2
Comparison 15 Lixisenatide versus placebo, Outcome 2 HbA1c
Analysis 15.3
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.3
Comparison 15 Lixisenatide versus placebo, Outcome 3 Symptomatic hypoglycaemia.
Analysis 15.4
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.4
Comparison 15 Lixisenatide versus placebo, Outcome 4 Weight change (kg).
Analysis 15.6
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.6
Comparison 15 Lixisenatide versus placebo, Outcome 6 Fasting plasma glucose (mmol/L).
Analysis 15.7
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.7
Comparison 15 Lixisenatide versus placebo, Outcome 7 Post‐prandial glucose (mmol/L).
Analysis 15.8
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.8
Comparison 15 Lixisenatide versus placebo, Outcome 8 Average self‐monitored 7‐point blood glucose (mmol/L).
Analysis 16.1
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.1
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 1 HbA1c.
Analysis 16.3
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.3
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 3 HbA1c
Analysis 16.4
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.4
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 4 Hypoglycaemia.
Analysis 16.5
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.5
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 5 Weight change.
Analysis 16.8
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.8
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 8 Systolic blood pressure.
Analysis 16.10
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.10
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 17.1
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.1
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 1 HbA1c (%).
Analysis 17.3
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.3
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 3 HbA1c
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 4 Hypoglycaemia.
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 5 Weight change (kg).
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 8 Systolic blood pressure…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 10 Fasting plasma glucose…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo, Outcome 1 HbA1c (%).
Analysis 18.3
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.3
Comparison 18 Taspoglutide versus placebo, Outcome 3 HbA1c
Analysis 18.5
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.5
Comparison 18 Taspoglutide versus placebo, Outcome 5 Hypoglycaemia.
Analysis 18.7
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.7
Comparison 18 Taspoglutide versus placebo, Outcome 7 Weight change (kg).
Analysis 18.11
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.11
Comparison 18 Taspoglutide versus placebo, Outcome 11 Fasting plasma glucose (mmol/L).
Analysis 19.4
Comparison 19 LY2189265 versus placebo,…
Analysis 19.4
Comparison 19 LY2189265 versus placebo, Outcome 4 Weight change (kg).
Analysis 19.6
Comparison 19 LY2189265 versus placebo,…
Analysis 19.6
Comparison 19 LY2189265 versus placebo, Outcome 6 Systolic blood pressure (mm Hg).
Analysis 19.7
Comparison 19 LY2189265 versus placebo,…
Analysis 19.7
Comparison 19 LY2189265 versus placebo, Outcome 7 Diastolic blood pressure (mm Hg).
Analysis 20.1
Comparison 20 GLP‐1 agonist versus…
Analysis 20.1
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 1 HbA1c.
Analysis 20.2
Comparison 20 GLP‐1 agonist versus…
Analysis 20.2
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 2 HbA1c
Analysis 20.3
Comparison 20 GLP‐1 agonist versus…
Analysis 20.3
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 3 Hypoglycaemia.
Analysis 20.5
Comparison 20 GLP‐1 agonist versus…
Analysis 20.5
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 5 Weight change.
Analysis 20.9
Comparison 20 GLP‐1 agonist versus…
Analysis 20.9
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 9 Systolic blood pressure.
Analysis 20.10
Comparison 20 GLP‐1 agonist versus…
Analysis 20.10
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 20.12
Comparison 20 GLP‐1 agonist versus…
Analysis 20.12
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 12 Triglycerides (mmol/L).
Analysis 20.13
Comparison 20 GLP‐1 agonist versus…
Analysis 20.13
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 13 Total cholesterol (mmol/L).
Analysis 20.14
Comparison 20 GLP‐1 agonist versus…
Analysis 20.14
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 14 HDL‐cholesterol (mmol/L).
Analysis 20.15
Comparison 20 GLP‐1 agonist versus…
Analysis 20.15
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 15 LDL‐cholesterol (mmol/L).
- [Efficacy of GLP-1-analogs in type 2 diabetes mellitus].Schütt M. Schütt M. Dtsch Med Wochenschr. 2013 Jan;138(1-2):15. doi: 10.1055/s-0032-1329135. Epub 2012 Dec 18. Dtsch Med Wochenschr. 2013. PMID: 23250688 German. No abstract available.
- Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Hemmingsen B, et al. Cochrane Database Syst Rev. 2017 May 10;5(5):CD012204. doi: 10.1002/14651858.CD012204.pub2. Cochrane Database Syst Rev. 2017. PMID: 28489279 Free PMC article. Review.
- Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis.Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR. Shyangdan DS, et al. BMC Endocr Disord. 2010 Dec 9;10:20. doi: 10.1186/1472-6823-10-20. BMC Endocr Disord. 2010. PMID: 21143938 Free PMC article.
- Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S. Waugh N, et al. Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Health Technol Assess. 2010. PMID: 20646668 Review.
- Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Htike ZZ, et al. Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17. Diabetes Obes Metab. 2017. PMID: 27981757 Review.
- Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.Pinelli NR, Hurren KM. Pinelli NR, et al. Ann Pharmacother. 2011 Jul;45(7-8):850-60. doi: 10.1345/aph.1Q024. Epub 2011 Jul 5. Ann Pharmacother. 2011. PMID: 21730278 Review.
- Effects of synbiotics supplementation on anthropometric and lipid profile parameters: Finding from an umbrella meta-analysis.Musazadeh V, Mohammadi Anilou M, Vajdi M, Karimi A, Sedgh Ahrabi S, Dehghan P. Musazadeh V, et al. Front Nutr. 2023 Feb 23;10:1121541. doi: 10.3389/fnut.2023.1121541. eCollection 2023. Front Nutr. 2023. PMID: 36908920 Free PMC article.
- Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients.Silva-Nunes J, Nascimento E, Louro J, Dores J, Laginha T, Gonçalves-Ferreira A, Alves M, Souto SB, Cunha N, Pina E, Duarte R, Raposo JF. Silva-Nunes J, et al. Metabolites. 2022 Nov 16;12(11):1121. doi: 10.3390/metabo12111121. Metabolites. 2022. PMID: 36422260 Free PMC article.
- Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data.Zhao Z, Tang Y, Hu Y, Zhu H, Chen X, Zhao B. Zhao Z, et al. Ann Transl Med. 2021 Sep;9(18):1482. doi: 10.21037/atm-21-4162. Ann Transl Med. 2021. PMID: 34734034 Free PMC article.
- Anti-Obesity Effect of Polygalin C Isolated from Polygala japonica Houtt. via Suppression of the Adipogenic and Lipogenic Factors in 3T3-L1 Adipocytes.Jee W, Lee SH, Ko HM, Jung JH, Chung WS, Jang HJ. Jee W, et al. Int J Mol Sci. 2021 Sep 27;22(19):10405. doi: 10.3390/ijms221910405. Int J Mol Sci. 2021. PMID: 34638751 Free PMC article.
- Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.Wong C, Lee MH, Yaow CYL, Chin YH, Goh XL, Ng CH, Lim AYL, Muthiah MD, Khoo CM. Wong C, et al. Front Endocrinol (Lausanne). 2021 Apr 9;12:609110. doi: 10.3389/fendo.2021.609110. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33897616 Free PMC article.
- Meta-Analysis
- Review
- Systematic Review
- Diabetes Mellitus, Type 2 / blood
- Diabetes Mellitus, Type 2 / drug therapy*
- Glucagon-Like Peptide 1 / analogs & derivatives*
- Glycated Hemoglobin / metabolism
- Humans
- Hypoglycemic Agents / therapeutic use*
- Randomized Controlled Trials as Topic
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Glucagon-Like Peptide 1
- Full Text Sources
- Medical
NCBI Literature Resources
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
![Analysis 11.3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-011-03.jpg)
![Analysis 11.5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-011-05.jpg)
![Analysis 11.9](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-011-09.jpg)
![Analysis 12.1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-012-01.jpg)
![Analysis 12.2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-012-02.jpg)
Analysis 12.3
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.3
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia.
Analysis 12.5
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.5
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 5 Weight change (kg).
Analysis 12.9
Comparison 12 Liraglutide 1.8 mg…
Analysis 12.9
Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma glucose…
Analysis 13.1
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.1
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 1 HbA1c (%).
Analysis 13.2
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.2
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 2 HbA1c
Analysis 13.3
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.3
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia (mild/moderate/overall).
Analysis 13.5
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.5
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change…
Analysis 13.7
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.7
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood…
Analysis 13.9
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.9
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma…
Analysis 14.1
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.1
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 1 HbA1c (%).
Analysis 14.2
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.2
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 2 HbA1c
Analysis 14.3
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.3
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia.
Analysis 14.5
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.5
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change…
Analysis 14.7
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.7
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood…
Analysis 14.9
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.9
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma…
Analysis 15.2
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.2
Comparison 15 Lixisenatide versus placebo, Outcome 2 HbA1c
Analysis 15.3
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.3
Comparison 15 Lixisenatide versus placebo, Outcome 3 Symptomatic hypoglycaemia.
Analysis 15.4
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.4
Comparison 15 Lixisenatide versus placebo, Outcome 4 Weight change (kg).
Analysis 15.6
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.6
Comparison 15 Lixisenatide versus placebo, Outcome 6 Fasting plasma glucose (mmol/L).
Analysis 15.7
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.7
Comparison 15 Lixisenatide versus placebo, Outcome 7 Post‐prandial glucose (mmol/L).
Analysis 15.8
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.8
Comparison 15 Lixisenatide versus placebo, Outcome 8 Average self‐monitored 7‐point blood glucose (mmol/L).
Analysis 16.1
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.1
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 1 HbA1c.
Analysis 16.3
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.3
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 3 HbA1c
Analysis 16.4
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.4
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 4 Hypoglycaemia.
Analysis 16.5
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.5
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 5 Weight change.
Analysis 16.8
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.8
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 8 Systolic blood pressure.
Analysis 16.10
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.10
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 17.1
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.1
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 1 HbA1c (%).
Analysis 17.3
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.3
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 3 HbA1c
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 4 Hypoglycaemia.
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 5 Weight change (kg).
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 8 Systolic blood pressure…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 10 Fasting plasma glucose…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo, Outcome 1 HbA1c (%).
Analysis 18.3
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.3
Comparison 18 Taspoglutide versus placebo, Outcome 3 HbA1c
Analysis 18.5
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.5
Comparison 18 Taspoglutide versus placebo, Outcome 5 Hypoglycaemia.
Analysis 18.7
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.7
Comparison 18 Taspoglutide versus placebo, Outcome 7 Weight change (kg).
Analysis 18.11
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.11
Comparison 18 Taspoglutide versus placebo, Outcome 11 Fasting plasma glucose (mmol/L).
Analysis 19.4
Comparison 19 LY2189265 versus placebo,…
Analysis 19.4
Comparison 19 LY2189265 versus placebo, Outcome 4 Weight change (kg).
Analysis 19.6
Comparison 19 LY2189265 versus placebo,…
Analysis 19.6
Comparison 19 LY2189265 versus placebo, Outcome 6 Systolic blood pressure (mm Hg).
Analysis 19.7
Comparison 19 LY2189265 versus placebo,…
Analysis 19.7
Comparison 19 LY2189265 versus placebo, Outcome 7 Diastolic blood pressure (mm Hg).
Analysis 20.1
Comparison 20 GLP‐1 agonist versus…
Analysis 20.1
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 1 HbA1c.
Analysis 20.2
Comparison 20 GLP‐1 agonist versus…
Analysis 20.2
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 2 HbA1c
Analysis 20.3
Comparison 20 GLP‐1 agonist versus…
Analysis 20.3
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 3 Hypoglycaemia.
Analysis 20.5
Comparison 20 GLP‐1 agonist versus…
Analysis 20.5
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 5 Weight change.
Analysis 20.9
Comparison 20 GLP‐1 agonist versus…
Analysis 20.9
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 9 Systolic blood pressure.
Analysis 20.10
Comparison 20 GLP‐1 agonist versus…
Analysis 20.10
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 20.12
Comparison 20 GLP‐1 agonist versus…
Analysis 20.12
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 12 Triglycerides (mmol/L).
Analysis 20.13
Comparison 20 GLP‐1 agonist versus…
Analysis 20.13
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 13 Total cholesterol (mmol/L).
Analysis 20.14
Comparison 20 GLP‐1 agonist versus…
Analysis 20.14
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 14 HDL‐cholesterol (mmol/L).
Analysis 20.15
Comparison 20 GLP‐1 agonist versus…
Analysis 20.15
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 15 LDL‐cholesterol (mmol/L).
- [Efficacy of GLP-1-analogs in type 2 diabetes mellitus].Schütt M. Schütt M. Dtsch Med Wochenschr. 2013 Jan;138(1-2):15. doi: 10.1055/s-0032-1329135. Epub 2012 Dec 18. Dtsch Med Wochenschr. 2013. PMID: 23250688 German. No abstract available.
- Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Hemmingsen B, et al. Cochrane Database Syst Rev. 2017 May 10;5(5):CD012204. doi: 10.1002/14651858.CD012204.pub2. Cochrane Database Syst Rev. 2017. PMID: 28489279 Free PMC article. Review.
- Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis.Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR. Shyangdan DS, et al. BMC Endocr Disord. 2010 Dec 9;10:20. doi: 10.1186/1472-6823-10-20. BMC Endocr Disord. 2010. PMID: 21143938 Free PMC article.
- Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S. Waugh N, et al. Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Health Technol Assess. 2010. PMID: 20646668 Review.
- Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Htike ZZ, et al. Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17. Diabetes Obes Metab. 2017. PMID: 27981757 Review.
- Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.Pinelli NR, Hurren KM. Pinelli NR, et al. Ann Pharmacother. 2011 Jul;45(7-8):850-60. doi: 10.1345/aph.1Q024. Epub 2011 Jul 5. Ann Pharmacother. 2011. PMID: 21730278 Review.
- Effects of synbiotics supplementation on anthropometric and lipid profile parameters: Finding from an umbrella meta-analysis.Musazadeh V, Mohammadi Anilou M, Vajdi M, Karimi A, Sedgh Ahrabi S, Dehghan P. Musazadeh V, et al. Front Nutr. 2023 Feb 23;10:1121541. doi: 10.3389/fnut.2023.1121541. eCollection 2023. Front Nutr. 2023. PMID: 36908920 Free PMC article.
- Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients.Silva-Nunes J, Nascimento E, Louro J, Dores J, Laginha T, Gonçalves-Ferreira A, Alves M, Souto SB, Cunha N, Pina E, Duarte R, Raposo JF. Silva-Nunes J, et al. Metabolites. 2022 Nov 16;12(11):1121. doi: 10.3390/metabo12111121. Metabolites. 2022. PMID: 36422260 Free PMC article.
- Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data.Zhao Z, Tang Y, Hu Y, Zhu H, Chen X, Zhao B. Zhao Z, et al. Ann Transl Med. 2021 Sep;9(18):1482. doi: 10.21037/atm-21-4162. Ann Transl Med. 2021. PMID: 34734034 Free PMC article.
- Anti-Obesity Effect of Polygalin C Isolated from Polygala japonica Houtt. via Suppression of the Adipogenic and Lipogenic Factors in 3T3-L1 Adipocytes.Jee W, Lee SH, Ko HM, Jung JH, Chung WS, Jang HJ. Jee W, et al. Int J Mol Sci. 2021 Sep 27;22(19):10405. doi: 10.3390/ijms221910405. Int J Mol Sci. 2021. PMID: 34638751 Free PMC article.
- Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.Wong C, Lee MH, Yaow CYL, Chin YH, Goh XL, Ng CH, Lim AYL, Muthiah MD, Khoo CM. Wong C, et al. Front Endocrinol (Lausanne). 2021 Apr 9;12:609110. doi: 10.3389/fendo.2021.609110. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33897616 Free PMC article.
- Meta-Analysis
- Review
- Systematic Review
- Diabetes Mellitus, Type 2 / blood
- Diabetes Mellitus, Type 2 / drug therapy*
- Glucagon-Like Peptide 1 / analogs & derivatives*
- Glycated Hemoglobin / metabolism
- Humans
- Hypoglycemic Agents / therapeutic use*
- Randomized Controlled Trials as Topic
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Glucagon-Like Peptide 1
- Full Text Sources
- Medical
NCBI Literature Resources
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
![Analysis 12.3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-012-03.jpg)
![Analysis 12.5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-012-05.jpg)
![Analysis 12.9](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-012-09.jpg)
![Analysis 13.1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-013-01.jpg)
![Analysis 13.2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-013-02.jpg)
Analysis 13.3
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.3
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia (mild/moderate/overall).
Analysis 13.5
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.5
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change…
Analysis 13.7
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.7
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood…
Analysis 13.9
Comparison 13 Liraglutide 1.2 mg…
Analysis 13.9
Comparison 13 Liraglutide 1.2 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma…
Analysis 14.1
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.1
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 1 HbA1c (%).
Analysis 14.2
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.2
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 2 HbA1c
Analysis 14.3
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.3
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia.
Analysis 14.5
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.5
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change…
Analysis 14.7
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.7
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood…
Analysis 14.9
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.9
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma…
Analysis 15.2
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.2
Comparison 15 Lixisenatide versus placebo, Outcome 2 HbA1c
Analysis 15.3
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.3
Comparison 15 Lixisenatide versus placebo, Outcome 3 Symptomatic hypoglycaemia.
Analysis 15.4
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.4
Comparison 15 Lixisenatide versus placebo, Outcome 4 Weight change (kg).
Analysis 15.6
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.6
Comparison 15 Lixisenatide versus placebo, Outcome 6 Fasting plasma glucose (mmol/L).
Analysis 15.7
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.7
Comparison 15 Lixisenatide versus placebo, Outcome 7 Post‐prandial glucose (mmol/L).
Analysis 15.8
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.8
Comparison 15 Lixisenatide versus placebo, Outcome 8 Average self‐monitored 7‐point blood glucose (mmol/L).
Analysis 16.1
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.1
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 1 HbA1c.
Analysis 16.3
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.3
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 3 HbA1c
Analysis 16.4
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.4
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 4 Hypoglycaemia.
Analysis 16.5
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.5
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 5 Weight change.
Analysis 16.8
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.8
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 8 Systolic blood pressure.
Analysis 16.10
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.10
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 17.1
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.1
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 1 HbA1c (%).
Analysis 17.3
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.3
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 3 HbA1c
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 4 Hypoglycaemia.
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 5 Weight change (kg).
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 8 Systolic blood pressure…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 10 Fasting plasma glucose…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo, Outcome 1 HbA1c (%).
Analysis 18.3
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.3
Comparison 18 Taspoglutide versus placebo, Outcome 3 HbA1c
Analysis 18.5
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.5
Comparison 18 Taspoglutide versus placebo, Outcome 5 Hypoglycaemia.
Analysis 18.7
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.7
Comparison 18 Taspoglutide versus placebo, Outcome 7 Weight change (kg).
Analysis 18.11
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.11
Comparison 18 Taspoglutide versus placebo, Outcome 11 Fasting plasma glucose (mmol/L).
Analysis 19.4
Comparison 19 LY2189265 versus placebo,…
Analysis 19.4
Comparison 19 LY2189265 versus placebo, Outcome 4 Weight change (kg).
Analysis 19.6
Comparison 19 LY2189265 versus placebo,…
Analysis 19.6
Comparison 19 LY2189265 versus placebo, Outcome 6 Systolic blood pressure (mm Hg).
Analysis 19.7
Comparison 19 LY2189265 versus placebo,…
Analysis 19.7
Comparison 19 LY2189265 versus placebo, Outcome 7 Diastolic blood pressure (mm Hg).
Analysis 20.1
Comparison 20 GLP‐1 agonist versus…
Analysis 20.1
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 1 HbA1c.
Analysis 20.2
Comparison 20 GLP‐1 agonist versus…
Analysis 20.2
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 2 HbA1c
Analysis 20.3
Comparison 20 GLP‐1 agonist versus…
Analysis 20.3
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 3 Hypoglycaemia.
Analysis 20.5
Comparison 20 GLP‐1 agonist versus…
Analysis 20.5
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 5 Weight change.
Analysis 20.9
Comparison 20 GLP‐1 agonist versus…
Analysis 20.9
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 9 Systolic blood pressure.
Analysis 20.10
Comparison 20 GLP‐1 agonist versus…
Analysis 20.10
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 20.12
Comparison 20 GLP‐1 agonist versus…
Analysis 20.12
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 12 Triglycerides (mmol/L).
Analysis 20.13
Comparison 20 GLP‐1 agonist versus…
Analysis 20.13
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 13 Total cholesterol (mmol/L).
Analysis 20.14
Comparison 20 GLP‐1 agonist versus…
Analysis 20.14
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 14 HDL‐cholesterol (mmol/L).
Analysis 20.15
Comparison 20 GLP‐1 agonist versus…
Analysis 20.15
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 15 LDL‐cholesterol (mmol/L).
- [Efficacy of GLP-1-analogs in type 2 diabetes mellitus].Schütt M. Schütt M. Dtsch Med Wochenschr. 2013 Jan;138(1-2):15. doi: 10.1055/s-0032-1329135. Epub 2012 Dec 18. Dtsch Med Wochenschr. 2013. PMID: 23250688 German. No abstract available.
- Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Hemmingsen B, et al. Cochrane Database Syst Rev. 2017 May 10;5(5):CD012204. doi: 10.1002/14651858.CD012204.pub2. Cochrane Database Syst Rev. 2017. PMID: 28489279 Free PMC article. Review.
- Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis.Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR. Shyangdan DS, et al. BMC Endocr Disord. 2010 Dec 9;10:20. doi: 10.1186/1472-6823-10-20. BMC Endocr Disord. 2010. PMID: 21143938 Free PMC article.
- Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S. Waugh N, et al. Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Health Technol Assess. 2010. PMID: 20646668 Review.
- Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Htike ZZ, et al. Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17. Diabetes Obes Metab. 2017. PMID: 27981757 Review.
- Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.Pinelli NR, Hurren KM. Pinelli NR, et al. Ann Pharmacother. 2011 Jul;45(7-8):850-60. doi: 10.1345/aph.1Q024. Epub 2011 Jul 5. Ann Pharmacother. 2011. PMID: 21730278 Review.
- Effects of synbiotics supplementation on anthropometric and lipid profile parameters: Finding from an umbrella meta-analysis.Musazadeh V, Mohammadi Anilou M, Vajdi M, Karimi A, Sedgh Ahrabi S, Dehghan P. Musazadeh V, et al. Front Nutr. 2023 Feb 23;10:1121541. doi: 10.3389/fnut.2023.1121541. eCollection 2023. Front Nutr. 2023. PMID: 36908920 Free PMC article.
- Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients.Silva-Nunes J, Nascimento E, Louro J, Dores J, Laginha T, Gonçalves-Ferreira A, Alves M, Souto SB, Cunha N, Pina E, Duarte R, Raposo JF. Silva-Nunes J, et al. Metabolites. 2022 Nov 16;12(11):1121. doi: 10.3390/metabo12111121. Metabolites. 2022. PMID: 36422260 Free PMC article.
- Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data.Zhao Z, Tang Y, Hu Y, Zhu H, Chen X, Zhao B. Zhao Z, et al. Ann Transl Med. 2021 Sep;9(18):1482. doi: 10.21037/atm-21-4162. Ann Transl Med. 2021. PMID: 34734034 Free PMC article.
- Anti-Obesity Effect of Polygalin C Isolated from Polygala japonica Houtt. via Suppression of the Adipogenic and Lipogenic Factors in 3T3-L1 Adipocytes.Jee W, Lee SH, Ko HM, Jung JH, Chung WS, Jang HJ. Jee W, et al. Int J Mol Sci. 2021 Sep 27;22(19):10405. doi: 10.3390/ijms221910405. Int J Mol Sci. 2021. PMID: 34638751 Free PMC article.
- Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.Wong C, Lee MH, Yaow CYL, Chin YH, Goh XL, Ng CH, Lim AYL, Muthiah MD, Khoo CM. Wong C, et al. Front Endocrinol (Lausanne). 2021 Apr 9;12:609110. doi: 10.3389/fendo.2021.609110. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33897616 Free PMC article.
- Meta-Analysis
- Review
- Systematic Review
- Diabetes Mellitus, Type 2 / blood
- Diabetes Mellitus, Type 2 / drug therapy*
- Glucagon-Like Peptide 1 / analogs & derivatives*
- Glycated Hemoglobin / metabolism
- Humans
- Hypoglycemic Agents / therapeutic use*
- Randomized Controlled Trials as Topic
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Glucagon-Like Peptide 1
- Full Text Sources
- Medical
NCBI Literature Resources
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
![Analysis 13.3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-013-03.jpg)
![Analysis 13.5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-013-05.jpg)
![Analysis 13.7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-013-07.jpg)
![Analysis 13.9](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-013-09.jpg)
![Analysis 14.1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-014-01.jpg)
![Analysis 14.2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-014-02.jpg)
Analysis 14.3
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.3
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 3 Hypoglycaemia.
Analysis 14.5
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.5
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 5 Weight change…
Analysis 14.7
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.7
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 7 Systolic blood…
Analysis 14.9
Comparison 14 Liraglutide 1.8 mg…
Analysis 14.9
Comparison 14 Liraglutide 1.8 mg daily versus DPP‐4 inhibitors, Outcome 9 Fasting plasma…
Analysis 15.2
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.2
Comparison 15 Lixisenatide versus placebo, Outcome 2 HbA1c
Analysis 15.3
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.3
Comparison 15 Lixisenatide versus placebo, Outcome 3 Symptomatic hypoglycaemia.
Analysis 15.4
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.4
Comparison 15 Lixisenatide versus placebo, Outcome 4 Weight change (kg).
Analysis 15.6
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.6
Comparison 15 Lixisenatide versus placebo, Outcome 6 Fasting plasma glucose (mmol/L).
Analysis 15.7
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.7
Comparison 15 Lixisenatide versus placebo, Outcome 7 Post‐prandial glucose (mmol/L).
Analysis 15.8
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.8
Comparison 15 Lixisenatide versus placebo, Outcome 8 Average self‐monitored 7‐point blood glucose (mmol/L).
Analysis 16.1
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.1
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 1 HbA1c.
Analysis 16.3
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.3
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 3 HbA1c
Analysis 16.4
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.4
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 4 Hypoglycaemia.
Analysis 16.5
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.5
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 5 Weight change.
Analysis 16.8
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.8
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 8 Systolic blood pressure.
Analysis 16.10
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.10
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 17.1
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.1
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 1 HbA1c (%).
Analysis 17.3
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.3
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 3 HbA1c
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 4 Hypoglycaemia.
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 5 Weight change (kg).
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 8 Systolic blood pressure…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 10 Fasting plasma glucose…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo, Outcome 1 HbA1c (%).
Analysis 18.3
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.3
Comparison 18 Taspoglutide versus placebo, Outcome 3 HbA1c
Analysis 18.5
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.5
Comparison 18 Taspoglutide versus placebo, Outcome 5 Hypoglycaemia.
Analysis 18.7
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.7
Comparison 18 Taspoglutide versus placebo, Outcome 7 Weight change (kg).
Analysis 18.11
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.11
Comparison 18 Taspoglutide versus placebo, Outcome 11 Fasting plasma glucose (mmol/L).
Analysis 19.4
Comparison 19 LY2189265 versus placebo,…
Analysis 19.4
Comparison 19 LY2189265 versus placebo, Outcome 4 Weight change (kg).
Analysis 19.6
Comparison 19 LY2189265 versus placebo,…
Analysis 19.6
Comparison 19 LY2189265 versus placebo, Outcome 6 Systolic blood pressure (mm Hg).
Analysis 19.7
Comparison 19 LY2189265 versus placebo,…
Analysis 19.7
Comparison 19 LY2189265 versus placebo, Outcome 7 Diastolic blood pressure (mm Hg).
Analysis 20.1
Comparison 20 GLP‐1 agonist versus…
Analysis 20.1
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 1 HbA1c.
Analysis 20.2
Comparison 20 GLP‐1 agonist versus…
Analysis 20.2
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 2 HbA1c
Analysis 20.3
Comparison 20 GLP‐1 agonist versus…
Analysis 20.3
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 3 Hypoglycaemia.
Analysis 20.5
Comparison 20 GLP‐1 agonist versus…
Analysis 20.5
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 5 Weight change.
Analysis 20.9
Comparison 20 GLP‐1 agonist versus…
Analysis 20.9
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 9 Systolic blood pressure.
Analysis 20.10
Comparison 20 GLP‐1 agonist versus…
Analysis 20.10
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 20.12
Comparison 20 GLP‐1 agonist versus…
Analysis 20.12
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 12 Triglycerides (mmol/L).
Analysis 20.13
Comparison 20 GLP‐1 agonist versus…
Analysis 20.13
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 13 Total cholesterol (mmol/L).
Analysis 20.14
Comparison 20 GLP‐1 agonist versus…
Analysis 20.14
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 14 HDL‐cholesterol (mmol/L).
Analysis 20.15
Comparison 20 GLP‐1 agonist versus…
Analysis 20.15
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 15 LDL‐cholesterol (mmol/L).
- [Efficacy of GLP-1-analogs in type 2 diabetes mellitus].Schütt M. Schütt M. Dtsch Med Wochenschr. 2013 Jan;138(1-2):15. doi: 10.1055/s-0032-1329135. Epub 2012 Dec 18. Dtsch Med Wochenschr. 2013. PMID: 23250688 German. No abstract available.
- Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Hemmingsen B, et al. Cochrane Database Syst Rev. 2017 May 10;5(5):CD012204. doi: 10.1002/14651858.CD012204.pub2. Cochrane Database Syst Rev. 2017. PMID: 28489279 Free PMC article. Review.
- Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis.Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR. Shyangdan DS, et al. BMC Endocr Disord. 2010 Dec 9;10:20. doi: 10.1186/1472-6823-10-20. BMC Endocr Disord. 2010. PMID: 21143938 Free PMC article.
- Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S. Waugh N, et al. Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Health Technol Assess. 2010. PMID: 20646668 Review.
- Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Htike ZZ, et al. Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17. Diabetes Obes Metab. 2017. PMID: 27981757 Review.
- Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.Pinelli NR, Hurren KM. Pinelli NR, et al. Ann Pharmacother. 2011 Jul;45(7-8):850-60. doi: 10.1345/aph.1Q024. Epub 2011 Jul 5. Ann Pharmacother. 2011. PMID: 21730278 Review.
- Effects of synbiotics supplementation on anthropometric and lipid profile parameters: Finding from an umbrella meta-analysis.Musazadeh V, Mohammadi Anilou M, Vajdi M, Karimi A, Sedgh Ahrabi S, Dehghan P. Musazadeh V, et al. Front Nutr. 2023 Feb 23;10:1121541. doi: 10.3389/fnut.2023.1121541. eCollection 2023. Front Nutr. 2023. PMID: 36908920 Free PMC article.
- Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients.Silva-Nunes J, Nascimento E, Louro J, Dores J, Laginha T, Gonçalves-Ferreira A, Alves M, Souto SB, Cunha N, Pina E, Duarte R, Raposo JF. Silva-Nunes J, et al. Metabolites. 2022 Nov 16;12(11):1121. doi: 10.3390/metabo12111121. Metabolites. 2022. PMID: 36422260 Free PMC article.
- Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data.Zhao Z, Tang Y, Hu Y, Zhu H, Chen X, Zhao B. Zhao Z, et al. Ann Transl Med. 2021 Sep;9(18):1482. doi: 10.21037/atm-21-4162. Ann Transl Med. 2021. PMID: 34734034 Free PMC article.
- Anti-Obesity Effect of Polygalin C Isolated from Polygala japonica Houtt. via Suppression of the Adipogenic and Lipogenic Factors in 3T3-L1 Adipocytes.Jee W, Lee SH, Ko HM, Jung JH, Chung WS, Jang HJ. Jee W, et al. Int J Mol Sci. 2021 Sep 27;22(19):10405. doi: 10.3390/ijms221910405. Int J Mol Sci. 2021. PMID: 34638751 Free PMC article.
- Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.Wong C, Lee MH, Yaow CYL, Chin YH, Goh XL, Ng CH, Lim AYL, Muthiah MD, Khoo CM. Wong C, et al. Front Endocrinol (Lausanne). 2021 Apr 9;12:609110. doi: 10.3389/fendo.2021.609110. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33897616 Free PMC article.
- Meta-Analysis
- Review
- Systematic Review
- Diabetes Mellitus, Type 2 / blood
- Diabetes Mellitus, Type 2 / drug therapy*
- Glucagon-Like Peptide 1 / analogs & derivatives*
- Glycated Hemoglobin / metabolism
- Humans
- Hypoglycemic Agents / therapeutic use*
- Randomized Controlled Trials as Topic
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Glucagon-Like Peptide 1
- Full Text Sources
- Medical
NCBI Literature Resources
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
![Analysis 14.3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-014-03.jpg)
![Analysis 14.5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-014-05.jpg)
![Analysis 14.7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-014-07.jpg)
![Analysis 14.9](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-014-09.jpg)
![Analysis 15.2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-015-02.jpg)
Analysis 15.3
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.3
Comparison 15 Lixisenatide versus placebo, Outcome 3 Symptomatic hypoglycaemia.
Analysis 15.4
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.4
Comparison 15 Lixisenatide versus placebo, Outcome 4 Weight change (kg).
Analysis 15.6
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.6
Comparison 15 Lixisenatide versus placebo, Outcome 6 Fasting plasma glucose (mmol/L).
Analysis 15.7
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.7
Comparison 15 Lixisenatide versus placebo, Outcome 7 Post‐prandial glucose (mmol/L).
Analysis 15.8
Comparison 15 Lixisenatide versus placebo,…
Analysis 15.8
Comparison 15 Lixisenatide versus placebo, Outcome 8 Average self‐monitored 7‐point blood glucose (mmol/L).
Analysis 16.1
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.1
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 1 HbA1c.
Analysis 16.3
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.3
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 3 HbA1c
Analysis 16.4
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.4
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 4 Hypoglycaemia.
Analysis 16.5
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.5
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 5 Weight change.
Analysis 16.8
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.8
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 8 Systolic blood pressure.
Analysis 16.10
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.10
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 17.1
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.1
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 1 HbA1c (%).
Analysis 17.3
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.3
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 3 HbA1c
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 4 Hypoglycaemia.
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 5 Weight change (kg).
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 8 Systolic blood pressure…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 10 Fasting plasma glucose…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo, Outcome 1 HbA1c (%).
Analysis 18.3
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.3
Comparison 18 Taspoglutide versus placebo, Outcome 3 HbA1c
Analysis 18.5
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.5
Comparison 18 Taspoglutide versus placebo, Outcome 5 Hypoglycaemia.
Analysis 18.7
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.7
Comparison 18 Taspoglutide versus placebo, Outcome 7 Weight change (kg).
Analysis 18.11
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.11
Comparison 18 Taspoglutide versus placebo, Outcome 11 Fasting plasma glucose (mmol/L).
Analysis 19.4
Comparison 19 LY2189265 versus placebo,…
Analysis 19.4
Comparison 19 LY2189265 versus placebo, Outcome 4 Weight change (kg).
Analysis 19.6
Comparison 19 LY2189265 versus placebo,…
Analysis 19.6
Comparison 19 LY2189265 versus placebo, Outcome 6 Systolic blood pressure (mm Hg).
Analysis 19.7
Comparison 19 LY2189265 versus placebo,…
Analysis 19.7
Comparison 19 LY2189265 versus placebo, Outcome 7 Diastolic blood pressure (mm Hg).
Analysis 20.1
Comparison 20 GLP‐1 agonist versus…
Analysis 20.1
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 1 HbA1c.
Analysis 20.2
Comparison 20 GLP‐1 agonist versus…
Analysis 20.2
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 2 HbA1c
Analysis 20.3
Comparison 20 GLP‐1 agonist versus…
Analysis 20.3
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 3 Hypoglycaemia.
Analysis 20.5
Comparison 20 GLP‐1 agonist versus…
Analysis 20.5
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 5 Weight change.
Analysis 20.9
Comparison 20 GLP‐1 agonist versus…
Analysis 20.9
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 9 Systolic blood pressure.
Analysis 20.10
Comparison 20 GLP‐1 agonist versus…
Analysis 20.10
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 20.12
Comparison 20 GLP‐1 agonist versus…
Analysis 20.12
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 12 Triglycerides (mmol/L).
Analysis 20.13
Comparison 20 GLP‐1 agonist versus…
Analysis 20.13
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 13 Total cholesterol (mmol/L).
Analysis 20.14
Comparison 20 GLP‐1 agonist versus…
Analysis 20.14
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 14 HDL‐cholesterol (mmol/L).
Analysis 20.15
Comparison 20 GLP‐1 agonist versus…
Analysis 20.15
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 15 LDL‐cholesterol (mmol/L).
- [Efficacy of GLP-1-analogs in type 2 diabetes mellitus].Schütt M. Schütt M. Dtsch Med Wochenschr. 2013 Jan;138(1-2):15. doi: 10.1055/s-0032-1329135. Epub 2012 Dec 18. Dtsch Med Wochenschr. 2013. PMID: 23250688 German. No abstract available.
- Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Hemmingsen B, et al. Cochrane Database Syst Rev. 2017 May 10;5(5):CD012204. doi: 10.1002/14651858.CD012204.pub2. Cochrane Database Syst Rev. 2017. PMID: 28489279 Free PMC article. Review.
- Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis.Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR. Shyangdan DS, et al. BMC Endocr Disord. 2010 Dec 9;10:20. doi: 10.1186/1472-6823-10-20. BMC Endocr Disord. 2010. PMID: 21143938 Free PMC article.
- Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S. Waugh N, et al. Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Health Technol Assess. 2010. PMID: 20646668 Review.
- Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Htike ZZ, et al. Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17. Diabetes Obes Metab. 2017. PMID: 27981757 Review.
- Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.Pinelli NR, Hurren KM. Pinelli NR, et al. Ann Pharmacother. 2011 Jul;45(7-8):850-60. doi: 10.1345/aph.1Q024. Epub 2011 Jul 5. Ann Pharmacother. 2011. PMID: 21730278 Review.
- Effects of synbiotics supplementation on anthropometric and lipid profile parameters: Finding from an umbrella meta-analysis.Musazadeh V, Mohammadi Anilou M, Vajdi M, Karimi A, Sedgh Ahrabi S, Dehghan P. Musazadeh V, et al. Front Nutr. 2023 Feb 23;10:1121541. doi: 10.3389/fnut.2023.1121541. eCollection 2023. Front Nutr. 2023. PMID: 36908920 Free PMC article.
- Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients.Silva-Nunes J, Nascimento E, Louro J, Dores J, Laginha T, Gonçalves-Ferreira A, Alves M, Souto SB, Cunha N, Pina E, Duarte R, Raposo JF. Silva-Nunes J, et al. Metabolites. 2022 Nov 16;12(11):1121. doi: 10.3390/metabo12111121. Metabolites. 2022. PMID: 36422260 Free PMC article.
- Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data.Zhao Z, Tang Y, Hu Y, Zhu H, Chen X, Zhao B. Zhao Z, et al. Ann Transl Med. 2021 Sep;9(18):1482. doi: 10.21037/atm-21-4162. Ann Transl Med. 2021. PMID: 34734034 Free PMC article.
- Anti-Obesity Effect of Polygalin C Isolated from Polygala japonica Houtt. via Suppression of the Adipogenic and Lipogenic Factors in 3T3-L1 Adipocytes.Jee W, Lee SH, Ko HM, Jung JH, Chung WS, Jang HJ. Jee W, et al. Int J Mol Sci. 2021 Sep 27;22(19):10405. doi: 10.3390/ijms221910405. Int J Mol Sci. 2021. PMID: 34638751 Free PMC article.
- Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.Wong C, Lee MH, Yaow CYL, Chin YH, Goh XL, Ng CH, Lim AYL, Muthiah MD, Khoo CM. Wong C, et al. Front Endocrinol (Lausanne). 2021 Apr 9;12:609110. doi: 10.3389/fendo.2021.609110. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33897616 Free PMC article.
- Meta-Analysis
- Review
- Systematic Review
- Diabetes Mellitus, Type 2 / blood
- Diabetes Mellitus, Type 2 / drug therapy*
- Glucagon-Like Peptide 1 / analogs & derivatives*
- Glycated Hemoglobin / metabolism
- Humans
- Hypoglycemic Agents / therapeutic use*
- Randomized Controlled Trials as Topic
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Glucagon-Like Peptide 1
- Full Text Sources
- Medical
NCBI Literature Resources
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
![Analysis 15.3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-015-03.jpg)
![Analysis 15.4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-015-04.jpg)
![Analysis 15.6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-015-06.jpg)
![Analysis 15.7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-015-07.jpg)
![Analysis 15.8](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-015-08.jpg)
![Analysis 16.1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-016-01.jpg)
![Analysis 16.3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-016-03.jpg)
Analysis 16.4
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.4
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 4 Hypoglycaemia.
Analysis 16.5
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.5
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 5 Weight change.
Analysis 16.8
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.8
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 8 Systolic blood pressure.
Analysis 16.10
Comparison 16 Liraglutide 1.2 mg…
Analysis 16.10
Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 17.1
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.1
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 1 HbA1c (%).
Analysis 17.3
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.3
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 3 HbA1c
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 4 Hypoglycaemia.
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 5 Weight change (kg).
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 8 Systolic blood pressure…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 10 Fasting plasma glucose…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo, Outcome 1 HbA1c (%).
Analysis 18.3
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.3
Comparison 18 Taspoglutide versus placebo, Outcome 3 HbA1c
Analysis 18.5
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.5
Comparison 18 Taspoglutide versus placebo, Outcome 5 Hypoglycaemia.
Analysis 18.7
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.7
Comparison 18 Taspoglutide versus placebo, Outcome 7 Weight change (kg).
Analysis 18.11
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.11
Comparison 18 Taspoglutide versus placebo, Outcome 11 Fasting plasma glucose (mmol/L).
Analysis 19.4
Comparison 19 LY2189265 versus placebo,…
Analysis 19.4
Comparison 19 LY2189265 versus placebo, Outcome 4 Weight change (kg).
Analysis 19.6
Comparison 19 LY2189265 versus placebo,…
Analysis 19.6
Comparison 19 LY2189265 versus placebo, Outcome 6 Systolic blood pressure (mm Hg).
Analysis 19.7
Comparison 19 LY2189265 versus placebo,…
Analysis 19.7
Comparison 19 LY2189265 versus placebo, Outcome 7 Diastolic blood pressure (mm Hg).
Analysis 20.1
Comparison 20 GLP‐1 agonist versus…
Analysis 20.1
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 1 HbA1c.
Analysis 20.2
Comparison 20 GLP‐1 agonist versus…
Analysis 20.2
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 2 HbA1c
Analysis 20.3
Comparison 20 GLP‐1 agonist versus…
Analysis 20.3
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 3 Hypoglycaemia.
Analysis 20.5
Comparison 20 GLP‐1 agonist versus…
Analysis 20.5
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 5 Weight change.
Analysis 20.9
Comparison 20 GLP‐1 agonist versus…
Analysis 20.9
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 9 Systolic blood pressure.
Analysis 20.10
Comparison 20 GLP‐1 agonist versus…
Analysis 20.10
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 20.12
Comparison 20 GLP‐1 agonist versus…
Analysis 20.12
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 12 Triglycerides (mmol/L).
Analysis 20.13
Comparison 20 GLP‐1 agonist versus…
Analysis 20.13
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 13 Total cholesterol (mmol/L).
Analysis 20.14
Comparison 20 GLP‐1 agonist versus…
Analysis 20.14
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 14 HDL‐cholesterol (mmol/L).
Analysis 20.15
Comparison 20 GLP‐1 agonist versus…
Analysis 20.15
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 15 LDL‐cholesterol (mmol/L).
- [Efficacy of GLP-1-analogs in type 2 diabetes mellitus].Schütt M. Schütt M. Dtsch Med Wochenschr. 2013 Jan;138(1-2):15. doi: 10.1055/s-0032-1329135. Epub 2012 Dec 18. Dtsch Med Wochenschr. 2013. PMID: 23250688 German. No abstract available.
- Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Hemmingsen B, et al. Cochrane Database Syst Rev. 2017 May 10;5(5):CD012204. doi: 10.1002/14651858.CD012204.pub2. Cochrane Database Syst Rev. 2017. PMID: 28489279 Free PMC article. Review.
- Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis.Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR. Shyangdan DS, et al. BMC Endocr Disord. 2010 Dec 9;10:20. doi: 10.1186/1472-6823-10-20. BMC Endocr Disord. 2010. PMID: 21143938 Free PMC article.
- Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S. Waugh N, et al. Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Health Technol Assess. 2010. PMID: 20646668 Review.
- Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Htike ZZ, et al. Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17. Diabetes Obes Metab. 2017. PMID: 27981757 Review.
- Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.Pinelli NR, Hurren KM. Pinelli NR, et al. Ann Pharmacother. 2011 Jul;45(7-8):850-60. doi: 10.1345/aph.1Q024. Epub 2011 Jul 5. Ann Pharmacother. 2011. PMID: 21730278 Review.
- Effects of synbiotics supplementation on anthropometric and lipid profile parameters: Finding from an umbrella meta-analysis.Musazadeh V, Mohammadi Anilou M, Vajdi M, Karimi A, Sedgh Ahrabi S, Dehghan P. Musazadeh V, et al. Front Nutr. 2023 Feb 23;10:1121541. doi: 10.3389/fnut.2023.1121541. eCollection 2023. Front Nutr. 2023. PMID: 36908920 Free PMC article.
- Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients.Silva-Nunes J, Nascimento E, Louro J, Dores J, Laginha T, Gonçalves-Ferreira A, Alves M, Souto SB, Cunha N, Pina E, Duarte R, Raposo JF. Silva-Nunes J, et al. Metabolites. 2022 Nov 16;12(11):1121. doi: 10.3390/metabo12111121. Metabolites. 2022. PMID: 36422260 Free PMC article.
- Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data.Zhao Z, Tang Y, Hu Y, Zhu H, Chen X, Zhao B. Zhao Z, et al. Ann Transl Med. 2021 Sep;9(18):1482. doi: 10.21037/atm-21-4162. Ann Transl Med. 2021. PMID: 34734034 Free PMC article.
- Anti-Obesity Effect of Polygalin C Isolated from Polygala japonica Houtt. via Suppression of the Adipogenic and Lipogenic Factors in 3T3-L1 Adipocytes.Jee W, Lee SH, Ko HM, Jung JH, Chung WS, Jang HJ. Jee W, et al. Int J Mol Sci. 2021 Sep 27;22(19):10405. doi: 10.3390/ijms221910405. Int J Mol Sci. 2021. PMID: 34638751 Free PMC article.
- Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.Wong C, Lee MH, Yaow CYL, Chin YH, Goh XL, Ng CH, Lim AYL, Muthiah MD, Khoo CM. Wong C, et al. Front Endocrinol (Lausanne). 2021 Apr 9;12:609110. doi: 10.3389/fendo.2021.609110. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33897616 Free PMC article.
- Meta-Analysis
- Review
- Systematic Review
- Diabetes Mellitus, Type 2 / blood
- Diabetes Mellitus, Type 2 / drug therapy*
- Glucagon-Like Peptide 1 / analogs & derivatives*
- Glycated Hemoglobin / metabolism
- Humans
- Hypoglycemic Agents / therapeutic use*
- Randomized Controlled Trials as Topic
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Glucagon-Like Peptide 1
- Full Text Sources
- Medical
NCBI Literature Resources
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
![Analysis 16.4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-016-04.jpg)
![Analysis 16.5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-016-05.jpg)
![Analysis 16.8](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-016-08.jpg)
![Analysis 16.10](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-016-10.jpg)
![Analysis 17.1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-017-01.jpg)
![Analysis 17.3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-017-03.jpg)
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.4
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 4 Hypoglycaemia.
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.5
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 5 Weight change (kg).
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.8
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 8 Systolic blood pressure…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg…
Analysis 17.10
Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 10 Fasting plasma glucose…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.1
Comparison 18 Taspoglutide versus placebo, Outcome 1 HbA1c (%).
Analysis 18.3
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.3
Comparison 18 Taspoglutide versus placebo, Outcome 3 HbA1c
Analysis 18.5
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.5
Comparison 18 Taspoglutide versus placebo, Outcome 5 Hypoglycaemia.
Analysis 18.7
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.7
Comparison 18 Taspoglutide versus placebo, Outcome 7 Weight change (kg).
Analysis 18.11
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.11
Comparison 18 Taspoglutide versus placebo, Outcome 11 Fasting plasma glucose (mmol/L).
Analysis 19.4
Comparison 19 LY2189265 versus placebo,…
Analysis 19.4
Comparison 19 LY2189265 versus placebo, Outcome 4 Weight change (kg).
Analysis 19.6
Comparison 19 LY2189265 versus placebo,…
Analysis 19.6
Comparison 19 LY2189265 versus placebo, Outcome 6 Systolic blood pressure (mm Hg).
Analysis 19.7
Comparison 19 LY2189265 versus placebo,…
Analysis 19.7
Comparison 19 LY2189265 versus placebo, Outcome 7 Diastolic blood pressure (mm Hg).
Analysis 20.1
Comparison 20 GLP‐1 agonist versus…
Analysis 20.1
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 1 HbA1c.
Analysis 20.2
Comparison 20 GLP‐1 agonist versus…
Analysis 20.2
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 2 HbA1c
Analysis 20.3
Comparison 20 GLP‐1 agonist versus…
Analysis 20.3
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 3 Hypoglycaemia.
Analysis 20.5
Comparison 20 GLP‐1 agonist versus…
Analysis 20.5
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 5 Weight change.
Analysis 20.9
Comparison 20 GLP‐1 agonist versus…
Analysis 20.9
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 9 Systolic blood pressure.
Analysis 20.10
Comparison 20 GLP‐1 agonist versus…
Analysis 20.10
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 20.12
Comparison 20 GLP‐1 agonist versus…
Analysis 20.12
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 12 Triglycerides (mmol/L).
Analysis 20.13
Comparison 20 GLP‐1 agonist versus…
Analysis 20.13
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 13 Total cholesterol (mmol/L).
Analysis 20.14
Comparison 20 GLP‐1 agonist versus…
Analysis 20.14
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 14 HDL‐cholesterol (mmol/L).
Analysis 20.15
Comparison 20 GLP‐1 agonist versus…
Analysis 20.15
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 15 LDL‐cholesterol (mmol/L).
- [Efficacy of GLP-1-analogs in type 2 diabetes mellitus].Schütt M. Schütt M. Dtsch Med Wochenschr. 2013 Jan;138(1-2):15. doi: 10.1055/s-0032-1329135. Epub 2012 Dec 18. Dtsch Med Wochenschr. 2013. PMID: 23250688 German. No abstract available.
- Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Hemmingsen B, et al. Cochrane Database Syst Rev. 2017 May 10;5(5):CD012204. doi: 10.1002/14651858.CD012204.pub2. Cochrane Database Syst Rev. 2017. PMID: 28489279 Free PMC article. Review.
- Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis.Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR. Shyangdan DS, et al. BMC Endocr Disord. 2010 Dec 9;10:20. doi: 10.1186/1472-6823-10-20. BMC Endocr Disord. 2010. PMID: 21143938 Free PMC article.
- Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S. Waugh N, et al. Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Health Technol Assess. 2010. PMID: 20646668 Review.
- Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Htike ZZ, et al. Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17. Diabetes Obes Metab. 2017. PMID: 27981757 Review.
- Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.Pinelli NR, Hurren KM. Pinelli NR, et al. Ann Pharmacother. 2011 Jul;45(7-8):850-60. doi: 10.1345/aph.1Q024. Epub 2011 Jul 5. Ann Pharmacother. 2011. PMID: 21730278 Review.
- Effects of synbiotics supplementation on anthropometric and lipid profile parameters: Finding from an umbrella meta-analysis.Musazadeh V, Mohammadi Anilou M, Vajdi M, Karimi A, Sedgh Ahrabi S, Dehghan P. Musazadeh V, et al. Front Nutr. 2023 Feb 23;10:1121541. doi: 10.3389/fnut.2023.1121541. eCollection 2023. Front Nutr. 2023. PMID: 36908920 Free PMC article.
- Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients.Silva-Nunes J, Nascimento E, Louro J, Dores J, Laginha T, Gonçalves-Ferreira A, Alves M, Souto SB, Cunha N, Pina E, Duarte R, Raposo JF. Silva-Nunes J, et al. Metabolites. 2022 Nov 16;12(11):1121. doi: 10.3390/metabo12111121. Metabolites. 2022. PMID: 36422260 Free PMC article.
- Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data.Zhao Z, Tang Y, Hu Y, Zhu H, Chen X, Zhao B. Zhao Z, et al. Ann Transl Med. 2021 Sep;9(18):1482. doi: 10.21037/atm-21-4162. Ann Transl Med. 2021. PMID: 34734034 Free PMC article.
- Anti-Obesity Effect of Polygalin C Isolated from Polygala japonica Houtt. via Suppression of the Adipogenic and Lipogenic Factors in 3T3-L1 Adipocytes.Jee W, Lee SH, Ko HM, Jung JH, Chung WS, Jang HJ. Jee W, et al. Int J Mol Sci. 2021 Sep 27;22(19):10405. doi: 10.3390/ijms221910405. Int J Mol Sci. 2021. PMID: 34638751 Free PMC article.
- Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.Wong C, Lee MH, Yaow CYL, Chin YH, Goh XL, Ng CH, Lim AYL, Muthiah MD, Khoo CM. Wong C, et al. Front Endocrinol (Lausanne). 2021 Apr 9;12:609110. doi: 10.3389/fendo.2021.609110. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33897616 Free PMC article.
- Meta-Analysis
- Review
- Systematic Review
- Diabetes Mellitus, Type 2 / blood
- Diabetes Mellitus, Type 2 / drug therapy*
- Glucagon-Like Peptide 1 / analogs & derivatives*
- Glycated Hemoglobin / metabolism
- Humans
- Hypoglycemic Agents / therapeutic use*
- Randomized Controlled Trials as Topic
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Glucagon-Like Peptide 1
- Full Text Sources
- Medical
NCBI Literature Resources
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
![Analysis 17.4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-017-04.jpg)
![Analysis 17.5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-017-05.jpg)
![Analysis 17.8](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-017-08.jpg)
![Analysis 17.10](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-017-10.jpg)
![Analysis 18.1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-018-01.jpg)
![Analysis 18.3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-018-03.jpg)
Analysis 18.5
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.5
Comparison 18 Taspoglutide versus placebo, Outcome 5 Hypoglycaemia.
Analysis 18.7
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.7
Comparison 18 Taspoglutide versus placebo, Outcome 7 Weight change (kg).
Analysis 18.11
Comparison 18 Taspoglutide versus placebo,…
Analysis 18.11
Comparison 18 Taspoglutide versus placebo, Outcome 11 Fasting plasma glucose (mmol/L).
Analysis 19.4
Comparison 19 LY2189265 versus placebo,…
Analysis 19.4
Comparison 19 LY2189265 versus placebo, Outcome 4 Weight change (kg).
Analysis 19.6
Comparison 19 LY2189265 versus placebo,…
Analysis 19.6
Comparison 19 LY2189265 versus placebo, Outcome 6 Systolic blood pressure (mm Hg).
Analysis 19.7
Comparison 19 LY2189265 versus placebo,…
Analysis 19.7
Comparison 19 LY2189265 versus placebo, Outcome 7 Diastolic blood pressure (mm Hg).
Analysis 20.1
Comparison 20 GLP‐1 agonist versus…
Analysis 20.1
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 1 HbA1c.
Analysis 20.2
Comparison 20 GLP‐1 agonist versus…
Analysis 20.2
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 2 HbA1c
Analysis 20.3
Comparison 20 GLP‐1 agonist versus…
Analysis 20.3
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 3 Hypoglycaemia.
Analysis 20.5
Comparison 20 GLP‐1 agonist versus…
Analysis 20.5
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 5 Weight change.
Analysis 20.9
Comparison 20 GLP‐1 agonist versus…
Analysis 20.9
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 9 Systolic blood pressure.
Analysis 20.10
Comparison 20 GLP‐1 agonist versus…
Analysis 20.10
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 20.12
Comparison 20 GLP‐1 agonist versus…
Analysis 20.12
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 12 Triglycerides (mmol/L).
Analysis 20.13
Comparison 20 GLP‐1 agonist versus…
Analysis 20.13
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 13 Total cholesterol (mmol/L).
Analysis 20.14
Comparison 20 GLP‐1 agonist versus…
Analysis 20.14
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 14 HDL‐cholesterol (mmol/L).
Analysis 20.15
Comparison 20 GLP‐1 agonist versus…
Analysis 20.15
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 15 LDL‐cholesterol (mmol/L).
- [Efficacy of GLP-1-analogs in type 2 diabetes mellitus].Schütt M. Schütt M. Dtsch Med Wochenschr. 2013 Jan;138(1-2):15. doi: 10.1055/s-0032-1329135. Epub 2012 Dec 18. Dtsch Med Wochenschr. 2013. PMID: 23250688 German. No abstract available.
- Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Hemmingsen B, et al. Cochrane Database Syst Rev. 2017 May 10;5(5):CD012204. doi: 10.1002/14651858.CD012204.pub2. Cochrane Database Syst Rev. 2017. PMID: 28489279 Free PMC article. Review.
- Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis.Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR. Shyangdan DS, et al. BMC Endocr Disord. 2010 Dec 9;10:20. doi: 10.1186/1472-6823-10-20. BMC Endocr Disord. 2010. PMID: 21143938 Free PMC article.
- Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S. Waugh N, et al. Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Health Technol Assess. 2010. PMID: 20646668 Review.
- Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Htike ZZ, et al. Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17. Diabetes Obes Metab. 2017. PMID: 27981757 Review.
- Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.Pinelli NR, Hurren KM. Pinelli NR, et al. Ann Pharmacother. 2011 Jul;45(7-8):850-60. doi: 10.1345/aph.1Q024. Epub 2011 Jul 5. Ann Pharmacother. 2011. PMID: 21730278 Review.
- Effects of synbiotics supplementation on anthropometric and lipid profile parameters: Finding from an umbrella meta-analysis.Musazadeh V, Mohammadi Anilou M, Vajdi M, Karimi A, Sedgh Ahrabi S, Dehghan P. Musazadeh V, et al. Front Nutr. 2023 Feb 23;10:1121541. doi: 10.3389/fnut.2023.1121541. eCollection 2023. Front Nutr. 2023. PMID: 36908920 Free PMC article.
- Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients.Silva-Nunes J, Nascimento E, Louro J, Dores J, Laginha T, Gonçalves-Ferreira A, Alves M, Souto SB, Cunha N, Pina E, Duarte R, Raposo JF. Silva-Nunes J, et al. Metabolites. 2022 Nov 16;12(11):1121. doi: 10.3390/metabo12111121. Metabolites. 2022. PMID: 36422260 Free PMC article.
- Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data.Zhao Z, Tang Y, Hu Y, Zhu H, Chen X, Zhao B. Zhao Z, et al. Ann Transl Med. 2021 Sep;9(18):1482. doi: 10.21037/atm-21-4162. Ann Transl Med. 2021. PMID: 34734034 Free PMC article.
- Anti-Obesity Effect of Polygalin C Isolated from Polygala japonica Houtt. via Suppression of the Adipogenic and Lipogenic Factors in 3T3-L1 Adipocytes.Jee W, Lee SH, Ko HM, Jung JH, Chung WS, Jang HJ. Jee W, et al. Int J Mol Sci. 2021 Sep 27;22(19):10405. doi: 10.3390/ijms221910405. Int J Mol Sci. 2021. PMID: 34638751 Free PMC article.
- Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.Wong C, Lee MH, Yaow CYL, Chin YH, Goh XL, Ng CH, Lim AYL, Muthiah MD, Khoo CM. Wong C, et al. Front Endocrinol (Lausanne). 2021 Apr 9;12:609110. doi: 10.3389/fendo.2021.609110. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33897616 Free PMC article.
- Meta-Analysis
- Review
- Systematic Review
- Diabetes Mellitus, Type 2 / blood
- Diabetes Mellitus, Type 2 / drug therapy*
- Glucagon-Like Peptide 1 / analogs & derivatives*
- Glycated Hemoglobin / metabolism
- Humans
- Hypoglycemic Agents / therapeutic use*
- Randomized Controlled Trials as Topic
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Glucagon-Like Peptide 1
- Full Text Sources
- Medical
![Analysis 18.5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-018-05.jpg)
![Analysis 18.7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-018-07.jpg)
![Analysis 18.11](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-018-11.jpg)
![Analysis 19.4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-019-04.jpg)
![Analysis 19.6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-019-06.jpg)
![Analysis 19.7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-019-07.jpg)
![Analysis 20.1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-020-01.jpg)
![Analysis 20.2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-020-02.jpg)
Analysis 20.3
Comparison 20 GLP‐1 agonist versus…
Analysis 20.3
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 3 Hypoglycaemia.
Analysis 20.5
Comparison 20 GLP‐1 agonist versus…
Analysis 20.5
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 5 Weight change.
Analysis 20.9
Comparison 20 GLP‐1 agonist versus…
Analysis 20.9
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 9 Systolic blood pressure.
Analysis 20.10
Comparison 20 GLP‐1 agonist versus…
Analysis 20.10
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 10 Fasting plasma glucose (mmol/L).
Analysis 20.12
Comparison 20 GLP‐1 agonist versus…
Analysis 20.12
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 12 Triglycerides (mmol/L).
Analysis 20.13
Comparison 20 GLP‐1 agonist versus…
Analysis 20.13
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 13 Total cholesterol (mmol/L).
Analysis 20.14
Comparison 20 GLP‐1 agonist versus…
Analysis 20.14
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 14 HDL‐cholesterol (mmol/L).
Analysis 20.15
Comparison 20 GLP‐1 agonist versus…
Analysis 20.15
Comparison 20 GLP‐1 agonist versus GLP‐1 agonist, Outcome 15 LDL‐cholesterol (mmol/L).
![Analysis 20.3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-020-03.jpg)
![Analysis 20.5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-020-05.jpg)
![Analysis 20.9](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-020-09.jpg)
![Analysis 20.10](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-020-10.jpg)
![Analysis 20.12](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-020-12.jpg)
![Analysis 20.13](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-020-13.jpg)
![Analysis 20.14](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-020-14.jpg)
![Analysis 20.15](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6486297/bin/nCD006423-CMP-020-15.jpg)
Source: PubMed